![Schematic representation of ROR family members.\
Schematic structure of the various human (h) and mouse (m) ROR isoforms. The DNA binding domain (DBD) and ligand binding domain (LBD), and activation function 2 (AF2) are indicated. The variable regions at the N-terminus of each ROR generated by alternative promoter usage and/or alternative slicing are indicated by patterned boxes on the left. The numbers on the right refer to the total number of amino acids in RORs. The different ROR isoforms identified in human and mouse are shown on the right (+/-).](nrs07003.f1){#fig1}

![Mechanism of action of RORs, physiological functions and roles in disease.\
RORs bind as a monomer to ROREs consisting of the GGTCA consensus core motif preceded by a 6A/T rich region. REV-ERBs can compete with RORs for binding to ROREs. RORs interact with coactivators or corepressors to positively or negatively regulate gene transcription. RORs are critical in the regulation of many physiological processes and may have a role in several pathologies. Although evidence has been provided indicating that certain ligands can modulate ROR transcriptional activity, whether ROR activity is modulated *in vivo* by endogenous ligands has yet to be determined. RORs might serve as potential novel targets for chemotherapeutic strategies to intervene in various disease processes.](nrs07003.f2){#fig2}

![Regulation of Purkinje cell maturation and cerebellar development by RORα.\
RORα regulates the expression of several genes in Purkinje cells. RORα becomes highly expressed in postmitotic Purkinje cells. It regulates their maturation, particularly dendritic differentiation. Dendritogenesis and the expression of several genes, including Shh, Itpr1, Pcp4, Calb1, Pcp2, and Slc1a6, normally expressed in mature Purkinje cells, are inhibited in RORα-deficient mice. The transcription of several of these genes is under direct control of RORα. Shh released by Purkinje cells interacts with Patched (Ptch) receptors on granule cell precursors, leading to activation of GLI transcription factors and the subsequent induction of proliferation-promoting genes. Reduced Shh expression in Purkinje cells from RORα-deficient mice is a major factor in the cerebellar atrophy observed in these mice. Cerebellar granule cells and Purkinje cells mutually interact (e.g., glutamatergic synapses).](nrs07003.f3){#fig3}

![RORγt is essential for the development of secondary lymphoid tissues.\
Lymphoid tissue inducer (LTi) cells are derived from fetal liver hematopoietic stem cells. This differentiation is accompanied by induction of the transcription factors Id2 and RORγt. LTi cells are recruited from the circulation by mesenchymal organizer cells. This is mediated by multiple receptor-ligand interactions. LTi cells are required for the development of lymph nodes, Peyer's patches, cryptopatches, and isolated lymphoid follicles (ILFs), which are thought to be derived from cryptopatches after the colonization of the intestine by bacteria. Recently, a novel lymphocyte population (NKp46^+^NK1.1^int^CD127^+^RORγt^hi^) was identified in the gut that may be derived from LTi-like cells in cryptopatches. RORγt is required for the generation and/or survival of LTi cells. The absence of LTi cells in RORγ-deficient mice is responsible for the lack of lymph nodes, Peyer's patches, cryptopatches, ILFs, and NKp46^+^NK1.1^int^CD127^+^RORγt^hi^ cells.](nrs07003.f4){#fig4}

![Role of RORγt in thymopoiesis.\
CD4^-^CD8^-^CD25^-^CD44^+^ (DN1) cells differentiate via DN2, DN3, DN4 into immature single positive (ISP) cells (CD3^-^CD4^-^CD8^low^). These cells subsequently differentiate into CD3^+^CD4^+^CD8^+^, DP thymocytes. RORγt, as well as Bcl-X~L~, are induced during the ISP-DP transition and again down-regulated during the differentiation of DP into CD4^+^ and CD8^+^ single positive cells. RORγt promotes the differentiation of ISP into DP cells and positively regulates the expression of the anti-apoptotic gene Bcl-X~L~. The latter enhances cell survival that subsequently promotes TCR rearrangements. Lack of RORγt expression inhibits the ISP-DP transition and reduces expression of Bcl-X~L~ in DP thymocytes. The latter results in accelerated apoptosis, reduced lifespan of DP thymocytes and, consequently, impaired TCRα rearrangements](nrs07003.f5){#fig5}

![Specific role for RORs in T cell lineage specification.\
Differentiation into different effector CD4^+^ T cell lineages, T helper (Th) 1, Th2, Th17, and T regulatory (T~reg~) cells is initiated through an interaction of dendritic cells with uncommitted (naïve) CD4^+^ T helper cells (Thp). The effector cell types are characterized by their synthesis of specific cytokines and their immuno-regulatory functions, as indicated on the right. The differentiation along different lineages involves different cytokines and the activation of distinct signaling cascades and transcription factors that result in the induction of additional cyto/chemokines and cyto/chemokine receptors, which may be part of positive and negative feedback loops. These cytokines and transcription factors may favor one cell lineage, while inhibiting another (not indicated). RORα and RORγt are induced during differentiation of Thp into the Th17 lineage and are critical for this lineage specification.](nrs07003.f6){#fig6}

![RORs are essential for Th17 cell differentiation and IL-17 expression.\
In the presence of TCR engagement, treatment of Thp cells with IL-6 plus TGFβ1 induces differentiation along the Th17 lineage and the activation of several genes, including IL-21, RORα, RORγt, IL-17, IL-17F, IL-22, and IL23R. Interaction of IL-23 and IL-21 with, respectively, IL23R and IL21R, reinforce Th17 differentiation and ROR expression. RORα and RORγt are required for the induction of IL-17, IL-17F, and IL23R, but not IL-21. A balance between FOXP3, which is induced by treatment with TGFβ alone, determines whether Thp cells differentiate into Th17 or T~reg~ cells. ATRA, through activation of RARα-RXR complexes, leads to increased FOXP3 and reduced ROR expression. FOXP3 inhibits RORα and RORγt transcriptional activity by interacting directly with RORs, thereby promoting differentiation along the T~reg~ lineage and inhibiting Th17 differentiation. Transcriptional regulators IRF4 and RUNX1 have also been implicated in the regulation of T~reg~ and Th17 differentiation.](nrs07003.f7){#fig7}

![RORs function as integrators of circadian oscillators and the rhythmic expression of downstream (metabolic) genes.\
The rhythmic expression of RORs is greatly dependent on the ROR isoform and tissue type. The core loop of the oscillator consists of the heterodimeric activators BMAL1 and CLOCK that activate the expression of PERs and CRYs. PER and CRY heterodimers interact with the BMAL1-CLOCK complex and negatively regulate their transcriptional activity. BMAL1 and CLOCK also activate the expression of REV-ERBs, which through their interaction with ROREs repress the transcription of several genes, including BMAL1, CRY1, and RORγ. REV-ERBs are critical in the rhythmic expression of BMAL1, CRY1 and RORγ in liver and several other tissues. RORγ does not affect the rhythmic expression, but increases the peak level of expression of BMAL1, CRY1, NPAS2, CLOCK, and REV-ERBα. The major function of RORγ appears to be to regulate the oscillatory pattern of expression of downstream target genes and, therefore, the rhythmic nature of several physiological processes. RORα exhibits a very weak rhythmic pattern of expression in liver and its major function also appears to be in regulating the (rhythmic) expression of downstream target genes. SIRT, through its deacetylase activity, promotes the degradation of PER and inhibits the interaction of CRY with BMAL1/CLOCK complex, thereby enhancing BMAL1/CLOCK transcriptional activity.](nrs07003.f8){#fig8}

Introduction
============

The cloning of several steroid hormone receptors in the 1980s led to an intense search by many laboratories for additional, novel members of the steroid hormone superfamily \[[@r8]; [@r56]; [@r75]; [@r76]; [@r91]; [@r172]; [@r236]; [@r322]\]. This resulted in the identification of a number of orphan receptors, including members of the retinoid-related orphan receptor (ROR) subfamily, which consists of RORα (NR1F1, RORA or RZRα)\[[@r14]; [@r92]; [@r93]\], RORβ (NR1F2, RORB or RZRβ) \[[@r7]; [@r33]; [@r269]\], and RORγ (NR1F3, RORC or TOR) \[[@r119]; [@r126]; [@r215]; [@r240]; [@r292]\]. ROR genes have been cloned from several mammalian species \[[@r14]; [@r33]; [@r93]; [@r119]; [@r126]; [@r147]; [@r166]; [@r215]; [@r240]\] and zebrafish \[[@r81]\]. ROR orthologues have also been identified in several lower species, including Drosophila hormone receptor 3 (DHR3) in *Drosophila melanogaster* \[[@r34]; [@r88]; [@r130]; [@r165]; [@r289]; [@r296]\], CHR3 in *Caenorhabditis elegans* \[[@r170]; [@r242]; [@r243]\], and MHR3 in *Manduca sexta* \[[@r127]; [@r175]; [@r176]; [@r179]; [@r241]; [@r261]\]. This article will review the current status of our knowledge of RORs, with emphasis on recent developments in their physiological functions, roles in pathophysiological processes, and their potential as pharmatherapeutical targets.

ROR structure and activity
==========================

ROR gene structure
------------------

The *RORα* gene maps to human chromosome 15q22.2 and spans a relatively large 730 kb genomic region comprised of 15 exons. The *RORβ* and *RORγ* genes map to 9q21.13, and 1q21.3 and cover approximately 188 and 24 kb, respectively. As a result of alternative promoter usage and exon splicing, each ROR gene generates several isoforms that differ only in their amino-terminus \[[@r7]; [@r93]; [@r108]; [@r119]; [@r126]; [@r206]; [@r215]; [@r292]; [@r310]\] ([Figure 1](#fig1){ref-type="fig"}). Four human RORα isoforms, referred to as RORα1-4, have been identified, while only two isoforms, α1 and α4, have been reported for mouse. The mouse *RORβ* gene generates two isoforms, β1 and β2, while humans appear to express only the RORβ1 isoform \[[@r7]\]. Both the mouse and human *RORγ* gene generate two isoforms, γ1 and γ2 \[[@r119]; [@r126]; [@r215]; [@r310]\]. Most isoforms exhibit a distinct pattern of tissue-specific expression and are involved in the regulation of different physiological processes and target genes. For example, human RORα3 is only found in human testis \[[@r286]\]. RORα1 and RORα4 are both prominently expressed in mouse cerebellum, while other mouse tissues express predominantly RORα4 \[[@r38]; [@r108]; [@r206]\]. RORγ2, most commonly referred to as RORγt, is exclusively detected in a few distinct cell types of the immune system, while RORγ1 expression is restricted to several other tissues \[[@r71]; [@r119]; [@r126]; [@r157]\]. In the mouse, expression of RORβ2 is restricted to the pineal gland and the retina, while RORβ1 is the predominant isoform in cerebral cortex, thalamus, and hypothalamus \[[@r7]\]. Although most ROR isoforms are under the control of different promoters, little is known about the transcriptional regulation of their tissue-specific expression.

ROR protein structure
---------------------

The ROR genes encode proteins of 459 to 556 amino acids ([Figure 1](#fig1){ref-type="fig"}). RORs exhibit a typical nuclear receptor domain structure consisting of four major functional domains: an N-terminal (A/B) domain followed by a highly conserved DNA-binding domain (DBD), a hinge domain, and a C-terminal ligand-binding domain (LBD) \[[@r76]; [@r91]; [@r148]; [@r225]; [@r249]; [@r287]; [@r322]\]. RORs regulate gene transcription by binding to specific DNA response elements (ROREs), consisting of the consensus RGGTCA core motif preceded by a 6-bp A/T-rich sequence, in the regulatory region of target genes \[[@r6]; [@r33]; [@r93]; [@r100]; [@r148]; [@r215]; [@r223]; [@r240]; [@r272]\]. RORs bind ROREs as a monomer and do not form heterodimers with retinoid-X receptors (RXRs) \[[@r7]; [@r33]; [@r93]; [@r100]; [@r215]; [@r223]; [@r240]; [@r272]\] ([Figure 2](#fig2){ref-type="fig"}). The interaction of RORs with ROREs is mediated by the P-box, the loop between the last two cysteines within the first zinc finger, which recognizes the core motif in the major groove, and the C-terminal extension, a 30 residue region just downstream from the two zinc fingers, which interacts with the 5'-AT-rich segment of the RORE in the adjacent minor groove \[[@r7]; [@r92]; [@r93]; [@r148]; [@r208]; [@r293]; [@r312]\]. Although RORα-γ and their different isoforms recognize closely-related ROREs, they exhibit distinct affinities for different ROREs. The amino-terminus (A/B domain) has been shown to play a critical role in conferring DNA binding specificity to the various ROR isoforms \[[@r7]; [@r92]; [@r93]; [@r293]; [@r312]\]. In addition to the RORE sequence and the amino terminus, the promoter context may play an important factor in determining which ROR is recruited to a particular RORE.

In several instances, crosstalk between nuclear receptor pathways involves competition between receptors for binding to the same response element. Such an interplay has been demonstrated between RORs and the nuclear receptors REV-ERBAα and REV-ERBβ (NR1D1 and D2, respectively), which recognize a subset of ROREs \[[@r30]; [@r92]\]. Because REV-ERB receptors act as transcriptional repressors, they are able to inhibit ROR-mediated transcriptional activation by competing with RORs for RORE binding \[[@r11]; [@r22]; [@r61]; [@r83]; [@r193]; [@r214]; [@r260]\] ([Figure 2](#fig2){ref-type="fig"}). Positive and negative regulation of RORE-mediated gene transcription by RORs and REV-ERBs have been reported to play a role in the control of brain and muscle ARNT-like 1 (BMAL1 or ARNTL) expression and may be part of several other regulatory feedback loops \[[@r2]; [@r5]; [@r86]; [@r104]; [@r234]; [@r254]; [@r301]\].

The LBDs of nuclear receptors are multifunctional and play a role in ligand binding, nuclear localization, receptor dimerization, and provide an interface for the interaction with coactivators and corepressors. X-ray structural analysis demonstrated that RORs have a secondary domain structure that is characteristic of that of nuclear receptors \[[@r154]; [@r284]; [@r285]\]. The LBDs of RORs contain, in addition to the typical 12 canonical α-helices (H1-12), two additional helices, H2' and H11'. The activation function 2 (AF2) in H12 consists of PLYKELF, which is 100% conserved among RORs ([Figure 1](#fig1){ref-type="fig"}). Deletion of the H12 or point mutations within H12 causes loss of the ROR transactivation activity and results in a dominant-negative ROR \[[@r173]; [@r180]\]. It is believed that H10 plays a critical role in the homo- and heterodimerization of nuclear receptors. Structure analyses revealed the presence of a kink in H10 of the LBD of RORα and RORβ that would greatly affect the dimerization capability of RORs \[[@r154]; [@r284]; [@r285]\]. This is consistent with the conclusion that RORs do not form homodimers or heterodimers with other RORs or RXRs.

RORs: ligand-dependent transcription factors
--------------------------------------------

Crystallography provided not only insights into the structure of the LBD, but also into size of the ligand binding pockets of RORs \[[@r154]; [@r284]\]. The ligand-binding pocket of RORβ was calculated to be 766 Å^3^, similar to that of RORα (722 Å^3^). Homology modeling predicted that the ligand binding pocket of RORγ is similar in size (705 Å^3^), but different in shape. Cholesterol, 7-dehydrocholesterol, and cholesterol sulfate were identified as RORα agonists \[[@r153]; [@r154]\]. They were found to bind RORα in a reversible manner and to enhance RORE-dependent transcriptional activation by RORα in cells maintained in cholesterol-depleted medium. On this basis, it has been suggested that RORα might function as a lipid sensor and be implicated in the regulation of lipid metabolism. The latter would be consistent with reports indicating that RORα regulates the expression of several genes involved in lipid metabolism \[[@r24]; [@r143]; [@r154]; [@r157]; [@r181]; [@r182]; [@r188]; [@r200]; [@r313]\]. However, whether cholesterol and cholesterol sulfate metabolites function as genuine physiological agonists of RORα, and whether other structurally-related lipids serve as endogenous ligands of RORα, needs to be established.

X-ray structure analysis of the RORβ(LBD) identified stearic acid as a fortuitously-captured ligand that appeared to act as a stabilizer by filling the ligand-binding pocket, rather than as a functional ligand \[[@r284]\]. Subsequently, several retinoids, including all-*trans* retinoic acid (ATRA) and the synthetic retinoid ALRT 1550 (ALRT), were identified as functional ligands for RORβ \[[@r285]\]. ATRA and ALRT 1550 were able to bind RORβ(LBD) reversibly and with high affinity and reduced RORβ-mediated transcriptional activation, suggesting that they act as partial antagonists. These retinoids were also able to bind RORγ and inhibit RORγ-mediated transactivation, but did not bind RORα or affect RORα-induced transactivation \[[@r285]\]. Interestingly, repression of RORβ-mediated transcription was observed only in neuronal cells and not in other cell types tested, indicating that this antagonism may be rather cell type-dependent and involve an interaction with (a) neuronal cell-specific RORβ repressor(s) \[[@r285]\]. Future studies have to determine whether ATRA acts as a genuine physiological ligand of RORβ and RORγ and establish the physiological significance of such an interaction in neuronal and non-neuronal cells.

Although future research needs to determine whether *in vivo* ROR activity is regulated by endogenous ligands, these crystallographic and structural studies do support the concept that ROR activity can be modulated by specific endogenous and/or synthetic (ant)agonists \[[@r153]; [@r154]; [@r285]\]. This conclusion is highly relevant to the emerging roles of RORs in several pathologies, including inflammation, various autoimmune diseases, obesity, and asthma, and the promise that these receptors might serve as potential targets for pharmacological intervention in these diseases ([Figure 2](#fig2){ref-type="fig"}).

Interaction with coregulatory proteins
--------------------------------------

For many receptors, binding of a ligand functions as a switch that induces a conformational change in the receptor that involves a repositioning of H12 (AF2) \[[@r50]; [@r94]; [@r109]; [@r120]; [@r121]; [@r210]; [@r229]; [@r235]; [@r330]\]. When RORs are in a transcriptionally-active conformation, H12 with H3 and H4 form a hydrophobic cleft and a charge clamp that involves the participation of a conserved Lys in H3 and a conserved Glu in H12 within RORs \[[@r154]; [@r284]; [@r285]\]. The clamp serves as an interaction interface for LXXLL motifs present in coactivators and related motifs in corepressors \[[@r95]; [@r112]; [@r173]; [@r190]; [@r224]; [@r329]\]. Receptor:coactivator complexes, through their histone acetylase activity, induce histone acetylation that results in decompaction of chromatin and increased transcription of target genes \[[@r94]; [@r211]; [@r325]; [@r331]\], while receptor association with corepressor complexes leads to histone deacetylation and subsequently compaction of chromatin and repression of gene expression \[[@r129]; [@r131]; [@r229]\].

RORs interact with corepressors, as well as coactivators, suggesting that they can function both as repressors and activators of gene transcription. The coactivators NCOA1 (SRC1), NCOA2 (TIF2 or GRIP1), PGC-1α, p300, and CBP \[[@r10]; [@r95]; [@r109]; [@r112]; [@r146]; [@r147]; [@r173]; [@r180]; [@r182]; [@r190]; [@r193]; [@r329]\] and corepressors NCOR1, NCOR2, RIP140, and the neuronal interacting factor X (NIX1) \[[@r101]; [@r109]; [@r146]; [@r147]; [@r150]; [@r190]\] are among the coregulators found within ROR protein complexes. Recently, repression of ROR-mediated transcriptional activation by the forkhead box transcription factor p3 (FOXP3) was shown to depend on a direct interaction between RORs and FOXP3 \[[@r62]; [@r337]; [@r349]\].

Posttranslational modifications
-------------------------------

Posttranslational modifications, including phosphorylation, acetylation, ubiquitination and sumoylation, play an important role in regulating nuclear receptor activity and stability \[[@r79]; [@r250]\]. The ubiquitin (Ub)-proteasome system is intimately involved in chromatin structure remodeling and transcriptional control by nuclear receptors \[[@r48]; [@r54]; [@r137]; [@r161]; [@r251]; [@r316]\]. Proteasome-mediated ubiquitination is also an integral part of the mechanism by which ROR receptor signaling is controlled. Inhibition of the 26S proteasome complex by the proteasome inhibitor MG-132 results in an accumulation of ubiquitinated RORα protein and reduces the transcriptional activity of this receptor \[[@r222]\]. Similarly, the corepressor Hairless (Hr) \[[@r31]; [@r295]\], which functions as an effective repressor of ROR-mediated transcriptional activation, enhances RORα protein stability by protecting it from proteasome-mediated degradation \[[@r222]; [@r224]\]. Reports showing that various proteasome subunits, including proteasome subunit β type 6 (PSMB6) and the 26S ATPase subunit PSMC5, are part of ROR protein complexes, are consistent with a role of the proteasome system in the regulation of ROR transcriptional activity \[[@r10]; [@r147]\]. The ubiquitin-conjugating enzyme I (UBE2I or UBC9), which catalyzes sumoylation, was also found to interact with RORs. Whether UBE2I catalyzes ROR sumoylation and alters ROR activity needs to be established.

Recent studies demonstrated that activation of protein kinase C induces phosphorylation of RORα1 and inhibits RORα1-mediated transcriptional activation \[[@r65]\], while calmodulin-dependent kinase IV (CaMKIV) has been shown to enhance the transcriptional activity of RORα by a mechanism that does not involve phosphorylation of RORα by CaMKIV \[[@r156]\]. Extracellular signal-regulated kinase-2 (ERK2) has been reported to phosphorylate RORα4 *in vitro* at Thr^128^ \[[@r185]\]. Future studies are needed to determine the physiological significance of these different kinases on ROR activity and function.

RORs and development
====================

Critical role of RORα in cerebellar development
-----------------------------------------------

Although RORα is expressed in a variety of tissues, including testis, kidney, adipose and liver, it is most highly expressed in the brain, particularly in the cerebellum and thalamus \[[@r14]; [@r33]; [@r66]; [@r108]; [@r206]; [@r230]; [@r231]; [@r232]; [@r311]\]. The function of RORα in brain development has not been extensively studied beyond the cerebellum. A high level of RORα expression was observed in the cerebellar Purkinje cells, while RORα is not detected in the granule cell layer \[[@r135]; [@r205]; [@r230]; [@r267]; [@r280]\]. During Purkinje cell development, RORα expression is first observed at E12.5, just after Purkinje cell precursors exit the mitotic cycle and leave the ventricular zone to migrate along radial glia to form a temporary cerebellar plate-like structure \[[@r95]; [@r96]; [@r97]; [@r147]\].

RORα null mice, generated by targeted disruption of the RORα gene, display essentially an identical phenotype as homozygous *staggerer* mice (RORα^sg/sg^) \[[@r66]; [@r108]; [@r123]; [@r178]; [@r278]; [@r286]\]. This natural mutant strain carries a 6.4 kb intragenic insertion causing deletion of the fifth exon, encoding the beginning of the LBD, and a frameshift that results in a premature stop codon \[[@r96]; [@r108]\]. RORα-deficient mice exhibit several abnormalities, including thin long bones, suggesting a role for RORα in bone formation \[[@r217]\]. In addition, these mice display ataxia and severe cerebellar atrophy, characterized by significantly fewer Purkinje cells and a loss of cerebellar granule cells \[[@r59]; [@r60]; [@r66]; [@r96]; [@r108]; [@r122]; [@r123]; [@r177]; [@r178]; [@r278]; [@r286]\]. Although the morphology of the cerebellar cortex in young heterozygous (RORα^sg/+^) mice appears normal, upon aging, an accelerated loss of Purkinje and granule cells was observed \[[@r60]; [@r106]; [@r107]; [@r343]\].

At E17.5 of development, the number of Purkinje cells generated appears to be similar between WT and RORα^sg/sg^ mice \[[@r59]; [@r311]\]. However, by PND5, the number of Purkinje cells is dramatically reduced and cells appear disorganized. Surviving RORα^sg/sg^ Purkinje cells contain stunted dendritic arbors lacking distal spiny branchlets and are deficient in their assembly of mature synapses with granule cells, suggesting that dendritogenesis is impaired. This is accompanied by a lack of parallel fiber (PF) input and a persistence of multiple climbing fiber (CF) innervations \[[@r23]; [@r144]; [@r202]; [@r203]\]. Dysfunctional synapse formation between PF and Purkinje cells is associated with a delayed shift from the glutamate transporter Slc17a6 (VGluT2) into Slc17a7 (VGluT1) in PF terminals and to an altered distribution of the glutamate receptors, Grm1 and Grm2, in Purkinje cells \[[@r144]\]. Expression of RORα in RORα^sg/sg^ Purkinje cells was shown to restore normal dendritogenesis in organotypic cultures \[[@r23]\]. These observations indicated that RORα does not regulate the genesis of Purkinje cells, but rather their maturation, particularly dendritic differentiation ([Figure 3](#fig3){ref-type="fig"}). This concept was further supported by observations showing that several genes down-regulated in Purkinje cells of RORα^sg/sg^ mice encode proteins involved in the maturation of Purkinje cells. These include genes involved in signal-dependent calcium release, such as the calmodulin inhibitor *Pcp4*, the IP3 receptor (*Itpr1*) and its interacting partner *Cals1*, the calcium-transporting ATPase *Atp2a2*, and major intracellular calcium buffer 1 (*Calb1*) \[[@r95]; [@r96]; [@r108]; [@r216]\]. In addition, several genes linked to the glutamatergic pathway were expressed at reduced levels in RORα^sg/sg^ mice, including the glutamate receptor *Grm1*, the glutamate transporter *Slc1a6*, and its anchor *Spnb3*, encoding a brain-specific β-spectrin.

The promoter regulatory regions of several genes down-regulated in RORα^sg/sg^ Purkinje cells, including those of *Pcp2*, *Pcp4*, *Itpr1*, *Shh*, and *Slc1a6*, contain ROREs that bind RORα \[[@r95]; [@r96]; [@r275]\]. Chromatin immunoprecipitation (ChIP) analysis demonstrated that RORα is associated with these ROREs *in vivo*, suggesting that these genes are directly regulated by RORα. Moreover, these studies revealed the identity of several transcriptional mediators that are part of RORα transcription activation complexes at these ROREs. Interestingly, the composition of these RORα:coactivator complexes associated with different promoters exhibited a certain promoter specificity. For example, the RORα transactivation complex associated with the *Pcp2*-RORE contained TIP60 (Tat-interactive protein, 60 kD), and SRC-1; the *Slc1a6*-RORE bound complex contained CBP, TIP60, SRC-1, and GRIP-1; while the *Pcp4*-RORE associated complex contained β-catenin, SRC-1, p300, and TIP60 \[[@r95]\]. These results suggest that the sequence and the promoter context of the RORE play a critical role in determining the composition of the RORα:coactivator complex recruited to each promoter.

The development of Purkinje cells and granule cells is mutually dependent. Positioning and morphological differentiation of Purkinje cells depends on granule cells, while proliferation of granule precursors requires factors released by Purkinje cells \[[@r97]; [@r311]\]. At birth, the number of granule cells is somewhat reduced, and this becomes more prominent during the first weeks after birth. In adult RORα-deficient mice, the granular layer is very thin and depleted of granule cells \[[@r59]; [@r60]; [@r66]; [@r96]; [@r108]; [@r122]; [@r123]; [@r177]; [@r178]; [@r278]; [@r286]; [@r341]\]. Studies using WT:staggerer chimeras indicated that the depletion of cerebellar granule cells in RORα^sg/sg^ mice is related to abnormalities inherent to RORα^sg/sg^ Purkinje cells \[[@r122]; [@r123]\]. This is consistent with the high level of expression of RORα in Purkinje cells and the lack of RORα in cerebellar granule cells. Sonic hedgehog (Shh) released by Purkinje cells plays a critical role in the regulation of the proliferation of cerebellar granule cells \[[@r49]; [@r95]; [@r159]; [@r317]\] ([Figure 3](#fig3){ref-type="fig"}). Interaction of Shh with Patched (Ptch) receptors on cerebellar granule precursors results in the activation of GLI Krüppel-like zinc finger proteins and the subsequent transcriptional activation of *N-MYC* and other cell cycle regulatory genes. The expression of Shh in RORα^sg/sg^ Purkinje cells was found to be reduced several fold, suggesting that the repression of Shh may be a critical factor in the diminished proliferation of granule precursors \[[@r95]; [@r96]\]. This is consistent with the observed repression of several Shh target genes, including *N-MYC*, in the cerebellum of RORα^sg/sg^ mice. This hypothesis is further supported by experiments showing that Shh was able to enhance proliferation of granule precursor cells in sections of cerebellum from PND4 RORα^sg/sg^ mice and partially prevented the reduction in granule cells \[[@r23]\]. These observations indicate that the down-regulation of Shh in RORα^sg/sg^ mice is an important contributing factor in the development of cerebellar hypoplasia in these mice and that RORα functions as a positive regulator of *Shh* expression. ChIP analysis indicated that RORα regulates *Shh* expression directly through ROREs in the promoter regulatory region of the *Shh* gene. Moreover, these studies identified β-catenin and p300 as constituents of the RORα transactivation complex associated with the RORE in *Shh*. The association of β-catenin with RORα transactivation complexes suggests a link between Wnt and ROR signaling, and is consistent with a reported role for Wnt signaling in cerebellar development \[[@r265]; [@r320]\].

Link between RORα and spinocerebellar ataxia type 1 (SCA1)
----------------------------------------------------------

Comparison of gene expression profiles indicated a possible link between RORα and spinocerebellar ataxia type 1 (SCA1), an autosomal dominant inherited neurodegenerative disorder that is characterized by progressive loss of motor coordination, speech impairment, and problems swallowing \[[@r277]; [@r351]\]. SCA1 is caused by aberrant effects triggered by an expanded polyglutamine (polyQ) tract within the protein ataxin 1 (ATXN1), resulting in variable degrees of neurodegeneration, predominantly in the cerebellum (due to loss of Purkinje cells), brainstem, and spinal cord. Sca1\[82Q\] mutant mice, which express an Atxn1 protein containing an 82 glutamine repeat, develop severe ataxia and degeneration of Purkinje cells \[[@r29]\]. A considerable overlap was observed between genes repressed in the cerebellum of Sca1\[82Q\] mice and genes found to be regulated by RORα in Purkinje cells, suggesting a possible connection between the two \[[@r95]; [@r276]\]. Immunohistochemical analysis indicated that the level of RORα was significantly reduced in Purkinje cells from Sca1\[82Q\] mice \[[@r277]\]. This reduction was found to be, at least in part, due to a decrease in RORα protein stability. In addition, it was demonstrated that RORα and ATXN1 are part of the same protein complex. This association was indirect and mediated by a direct interaction of ATXN1 with the coactivator TIP60, which has been show to be part of several RORα-coactivator complexes in Purkinje cells \[[@r95]; [@r276]\]. It was concluded that decreased levels of RORα protein in SCA1 Purkinje cells causes reduced expression of RORα-target genes that are critical for Purkinje cell development and function, and consequently is an important contributory factor in the neurodegeneration observed in SCA1 \[[@r277]\].

Physiological Function of RORβ in brain and retina
--------------------------------------------------

RORβ exhibits a restricted pattern of expression that is limited to certain regions of the brain and retina \[[@r6]; [@r7]; [@r12]; [@r232]; [@r269]\]. During the period between E12.5 and PND5 of mouse development, RORβ is expressed in the neocortex and dorsal thalamus in a highly dynamic, spatiotemporal manner \[[@r147]; [@r232]\]. In adult brain, RORβ mRNA is most highly expressed in the cerebral cortex, thalamus, hypothalamus, suprachiasmatic nucleus (SCN), and the pineal gland, while little expression was detected in the cerebellum or hippocampus \[[@r6]; [@r7]; [@r269]; [@r290]\]. RORβ is also expressed in the anterior olfactory nucleus posterior and sensory cortices. These observations suggested that RORβ is highly restricted to several regions involved in the processing of sensory information.

Study of RORβ null mice provided several clues about the physiological function of RORβ. RORβ null mice exhibit several motor defects, including a 'duck-like' gait and an impairment in several neurological reflexes, e.g., hind paw clasping reflex \[[@r6]; [@r204]\]. RORβ null mice display several behavioral changes, including increased exploratory activity and reduced anxiety behavior, and olfactory deficits \[[@r204]\]. In addition, RORβ^-/-^ mice show a delayed onset of male fertility \[[@r6]\].

The relatively high expression in the retina and the development of retinal degeneration in RORβ^-/-^ mice suggested an important regulatory function for RORβ in this tissue \[[@r6]\]. At E17.5 of mouse and rat development, RORβ expression is detected in the formative ganglion cell layer and the neuroblastic layer \[[@r6]; [@r269]; [@r281]\]. By PND6, the neuroblastic layer has split into the inner nuclear layer of interneurons and the outer nuclear layer, where the photoreceptor cells, rods and cones, reside. At PND16 and older, RORβ is still expressed in all retinal layers, but most highly in the outermost part of the outer nuclear layer. RORβ^-/-^ mice exhibit several retinal developmental defects. At PND6, cell loss was observed in the ganglion layer, while the interneurons in the inner layer appeared in disarray. Although an outer nuclear layer was formed, it was significantly thinner than in WT retina, but maintained for several weeks. Rods and cones photoreceptors in the outer layer appeared disorganized and lacked outer and inner segments. These observations suggested that RORβ plays a key role in the maturation of photoreceptors, particularly the formation of the outer segments, the light sensing structures of cones and rods that contain opsin and rhodopsin, respectively \[[@r281]\].

In most mammals, color vision depends on the photopigments, S and M opsin, which are synthesized by distinct cone populations \[[@r72]\]. In WT mice, S opsin expression is observed at PND6, and by PND13 is concentrated to the outer segments of maturing cones; however, in RORβ^-/-^ mice, induction of S opsin (*Opn1sw*) is significantly delayed. After PND23, S opsin is detected at greatly reduced levels. Little difference in the induction of M opsin (*Opn1mw*) and thyroid hormone receptor *TRβ2*, which is essential for *Opn1mw* expression, was observed between WT and RORβ^-/-^ mice. The transcription factor CRX (cone-rod homeobox factor), which is critical for both S and M opsin gene expression, is normally expressed in rods and cones \[[@r281]\]. These data and histological studies suggested that RORβ is not a requirement for the initiation of differentiation of progenitors into photoreceptors, but specifically regulates their maturation, as illustrated by the reduced level of S opsin.

Study of the *Opn1sw* promoter provided further evidence that RORβ is an important regulator of *Opn1sw* expression. The proximal promoter region of *Opn1sw* contains two putative ROREs that are able to bind RORβ. Optimal activation of this promoter region was found to require a synergy between RORβ and CRX \[[@r281]\]. The latter is consistent with the co-expression of both transcription factors in the photoreceptor layer during the period when *Opn1sw* expression is induced. The activation of the *Opn1sw* promoter by RORβ was mediated principally through interaction with the most proximal RORE and, as expected, required both the DBD and AF2 domains of RORβ. Analysis of a transgene consisting of LacZ controlled by the *Opn1sw* proximal promoter region in mice showed that its expression was restricted to the photoreceptors with features of cones in the outer nuclear layer, while mutations in the ROREs totally abolished this expression. These observations indicate that RORβ is required for the induction of S opsin and support the conclusion that RORβ regulates *Opn1sw* transcription in a direct manner through ROREs within its proximal promoter region. In addition, they explain the greatly diminished expression of *Opn1sw* observed in the retina of RORβ^-/-^ mice.

Role for RORα in cone development
---------------------------------

Recent studies have indicated that RORα also plays a role in mouse retinal development \[[@r84]; [@r135]\]. In the retina, RORα expression is highly dynamic. It is first observed at E17 in the developing ganglion layer, while it is not detectable in the neuroblastic layer. At PND3, RORα was also found in the outer and inner border of the neuroblastic layer. In retina of adult mice, RORα is intensely expressed in the ganglion cell layer, the inner nuclear layer, and in cone photoreceptors in the outer layer, as indicated by its co-localization with both S and M opsin. Analysis of *Opn1sw* and *Opn1mw* expression showed that their level of expression was significantly reduced in RORα^sg/sg^ retina. Expression of cone arrestin (*Arr3*) was also diminished, whereas the expression of several other cone genes, including phosphodiesterases 6c and 6h (*Pde6c* and *Pde6h*) and cyclic nucleotide gated channel b3 (*Gngb3*), and the expression of the rod-specific gene rhodopsin (*Rho*) were unchanged. Expression of RORβ was also unaffected in RORα^sg/sg^ retina. As demonstrated for RORβ, RORα was shown to act in synergy with CRX to induce *Opn1sw* expression \[[@r84]\]. *In vivo* ChIP analysis supported the conclusion that *Opn1sw*, *Opn1mw*, and *Arr3* are direct targets of RORα regulation. Thus, both RORα and RORβ function as regulators of cone development and *Opn1sw*; however, in contrast to RORα, RORβ does not affect *Opn1mw* expression. These data suggest that although RORα and RORβ exhibit some functional redundancy, their functions in cone development appear largely distinct from each other.

Role of RORγ in the development of secondary lymphoid tissues
-------------------------------------------------------------

RORγ1 and RORγt (RORγ2) exhibit distinct patterns of tissue-specific expression. RORγ1 is expressed in many tissues, including liver, adipose, skeletal muscle, and kidney, while the expression of RORγt is exclusively expressed in a few distinct cell types of the immune system \[[@r69]; [@r70]; [@r146]; [@r147]; [@r189]\]. Mice deficient in RORγ expression lack lymph nodes and Peyer\'s patches (PPs), suggesting that RORγ is indispensable for lymph node organogenesis and development of PPs \[[@r69]; [@r71]; [@r117]; [@r147]; [@r148]; [@r149]; [@r174]; [@r189]; [@r190]; [@r292]\]. Lymphoid tissue inducer (LTi) cells play a critical role in the development of lymph nodes and PPs. LTi cells originate from hematopoietic precursor cells in the fetal liver and have been recently characterized as CD45^int^CD4^+^CD3^-^CD127(IL-7Rα)^+^Lin^-^ cells in mice and in humans as lineage-negative CD45^int^CD4^-^CD3^-^CD127^hi^Lin^-^ cells \[[@r45]; [@r69]; [@r212]; [@r213]\]. LTi cells are recruited to the lymph node anlagen through their interaction with mesenchymal organizer cells, specialized cells derived from differentiating mesenchymal cells \[[@r46]; [@r47]; [@r68]; [@r69]; [@r189]\] ([Figure 4](#fig4){ref-type="fig"}). This cell:cell interaction involves several positive feedback loops and amplifying mechanisms. Lymph node organogenesis is initiated by interaction of lymphotoxin α1β2 at the surface of LTi cells with their respective receptors on mesenchymal organizer cells. This leads to the induction of several adhesion molecules, including vascular cell adhesion molecule 1 (VCAM-1) and mucosal addressin cellular adhesion molecule 1 (MadCAM-1) and the subsequent production of homeostatic chemokines by mesenchymal organizer cells \[[@r46]; [@r47]; [@r68]; [@r189]; [@r228]; [@r342]\] ([Figure 4](#fig4){ref-type="fig"}). In addition to reinforcing the interaction between LTi and mesenchymal organizer cells, these interactions amplify the recruitment of additional LTi cells and promote the recruitment of other cells, such as monocytes and T and B lymphocytes, from the circulation \[[@r47]; [@r228]\]. Subsequent studies showed that LTi cells are absent from spleen, mesentery, and intestine of RORγ^-/-^ E18.5 embryos, indicating that RORγt plays a critical role in the generation and/or survival of LTi cells \[[@r68]; [@r69]\]. As a consequence, the lack of lymph nodes and PPs in RORγt- or RORγ-deficient mice is due to the absence of LTi cells.

Besides PPs and mesenteric lymph nodes, the intestinal immune system contains several other lymphoid cell compartments, including cryptopatches and isolated lymphoid follicles (ILFs) \[[@r68]; [@r294]\] ([Figure 4](#fig4){ref-type="fig"}). ILFs develop from cryptopatches in response to inflammatory innate immune signals generated by the colonization of the intestine by bacteria. Lin^-^cKit^+^CD127^+^CD44^+^ cells in cryptopatches and in ILFs express high levels of RORγt and appear to constitute the adult counterpart of LTi cells \[[@r68]; [@r70]\]. The deficiency in cryptopatches and ILFs observed in RORγ^-/-^ mice indicate that RORγt is essential for the development of these cell compartments and is due to the absence of these LTi-like cells in these mice.

Recent studies identified a novel lymphocyte population in the intestinal lamina propria that produces IL-22 and co-expresses RORγt and CD127, and natural killer (NK) cell markers NKp46 and NK1.1 (CD3^-^RORγt^hi^CD127^+^NKp46^+^NK1.1^int^) \[[@r45]; [@r197]; [@r266]\] ([Figure 4](#fig4){ref-type="fig"}). These cells are absent in RORγt-deficient mice. Because of its dependence on RORγt and its CD127^+^c-Kit^+^ phenotype, these NK cells resemble LTi cells, suggesting a possible link between the two cell types. LTi cells have been reported to be able to differentiate into NK and antigen presenting cells \[[@r212]; [@r213]\]. The basic helix-loop-helix transcription factor Id2, which as RORγt is expressed in LTi cells, is essential for both LTi and NK cell development \[[@r340]\]. In contrast, peripheral NK cells do not express RORγt and their number is unaffected in RORγ-deficient mice \[[@r292]\]. It is has been suggested that RORγt^hi^NKp46^+^NK1.1^int^ cells do not belong to the NK cell lineage, but may be derived from the Lin^-^Kit^+^CD127^+^RORγt^hi^ LTi-like cells in cryptopatches \[[@r45]; [@r197]; [@r266]\]. The precise role of these cells in normal intestinal mucosa immunity and pathology, including colitis, needs further study.

In contrast to lymph nodes and Peyer's patches, the development of several other lymphoid tissues, including nasal- and bronchial-associated lymphoid tissue (BALT and NALT), was undisturbed in RORγ^-/-^ mice, suggesting that the organogenesis of these lymphoid tissues involves a different mechanism \[[@r110]\].

Critical functions of RORγ in thymopoiesis
------------------------------------------

Several studies have demonstrated that RORγt plays a critical role in the regulation of thymopoiesis \[[@r105]; [@r116]; [@r119]; [@r126]; [@r146]; [@r147]; [@r174]; [@r215]; [@r240]; [@r292]\]. During thymopoiesis, T cell precursor CD25^-^CD44^+^CD4^-^CD8^-^ cells (DN1) differentiate successively via two intermediate stages, CD25^+^CD44^+^ (DN2) and CD25^+^CD44^-^ (DN3), into CD44^-^CD25^-^ (DN4) thymocytes ([Figure 5](#fig5){ref-type="fig"}). These cells then differentiate via immature single positive (ISP) cells (CD3^-^CD4^-^CD8^low^) into double positive CD4^+^CD8^+^ (DP) thymocytes \[[@r221]\]. After successful T cell receptor α (TCRα) gene rearrangement, DP cells expressing TCRαβ receptor undergo a careful selection process to eliminate thymocytes expressing nonfunctional or autoreactive TCR \[[@r283]; [@r346]\]. The positive selected DP thymocytes mature into single positive (SP) CD4^+^CD8^-^ helper and CD4^-^CD8^+^ cytotoxic T cells that then colonize the secondary lymphoid organs, including the spleen, lymph nodes, and PPs.

RORγt is transiently expressed during thymopoiesis \[[@r105]; [@r117]; [@r118]; [@r119]; [@r146]; [@r147]; [@r148]; [@r292]\] ([Figure 5](#fig5){ref-type="fig"}). It is undetectable in DN thymocytes and highly induced when ISP cells differentiate into DP thymocytes and again down-regulated when DP thymocytes differentiate into mature T lymphocytes. At birth and during early stages of life, RORγ null mice have a significantly smaller thymus compared to wild type mice as a result of a drastic reduction in the number of double positive DP and SP thymocytes, while the percentage of ISP thymocytes is greatly increased \[[@r69]; [@r148]; [@r149]; [@r174]; [@r292]\]. The accumulation of ISP cells in RORγ^-/-^ mice appears to be due to a delay in the differentiation of ISP into DP cells, suggesting a role for RORγt in the regulation of the ISP-DP transition \[[@r105]\]. In addition, DP thymocytes undergo massive apoptosis *in vivo* and *in vitro* \[[@r146]; [@r147]; [@r148]; [@r174]; [@r292]\]. The accelerated apoptosis of RORγ^-/-^ DP thymocytes is related to reduced expression of the anti-apoptotic gene *Bcl-X~L~*. This repression is an early and key event in accelerated apoptosis in RORγ^-/-^ thymocytes \[[@r292]; [@r329]\]. Thus, RORγ functions as a positive regulator of *Bcl-X~L~* expression and, as a result, promotes the survival of DP thymocytes, thereby enabling gene rearrangement \[[@r71]; [@r119]; [@r146]; [@r147]; [@r148]; [@r149]; [@r174]; [@r198]\].

Little is still understood about the mechanism by which *Bcl-X~L~* and *RORγt* expression are regulated during thymopoiesis. The reduced expression of *Bcl-X~L~* in RORγ^-/-^ mice and the observation that the induction and down-regulation of *Bcl-X~L~* and *RORγt* expression occur in parallel, are consistent with the concept that RORγt regulates *Bcl-X~L~* expression. Whether this regulation involves a direct or indirect mechanism has yet to be established. A recent study provided evidence for a link between early growth response gene 3 (*EGR3*) expression and the regulation of *RORγt* and *Bcl-X~L~* \[[@r326]; [@r327]\]. Pre-TCR signals transiently induce EGR3, which promotes proliferation, whereas the subsequent down-regulation of EGR3 leads to growth cessation and induction of *RORγt* and *Bcl-X~L~* needed for cell survival and proper gene rearrangement.

Analysis of gene expression profiles of thymocytes from WT and RORγ^-/-^ mice identified additional changes in gene expression, including repression of the transcription factor *EGR1*, Ngfi-A binding protein 2 (*NAB2*), and the glucocorticoid-induced transcript 1 (*GLCCI1*) \[[@r158]\]. One of the genes most dramatically repressed in thymocytes from RORγ^-/-^ mice is oligonucleotide/oligosaccharide-binding fold-containing 2a (*Obfc2a*, also named *NABP1*). The pattern of *Obfc2a* expression during thymopoiesis correlates with that of RORγt. Therefore, *Obfc2a* might be a potential RORγ target gene; alternatively, its down-regulation is just a consequence of the reduction in DP cells observed in RORγ^-/-^ mice. In summary, these studies indicate that RORγ plays a critical role in thymocyte homeostasis by regulating differentiation, proliferation, and apoptosis of thymocytes \[[@r117]; [@r146]; [@r147]; [@r148]; [@r324]\].

Role of RORα in lymphocyte development
--------------------------------------

Both the spleen and the thymus are significantly smaller in RORα-deficient mice, suggesting that RORα may have a role in the regulation of thymopoiesis and lymphocyte development \[[@r67]; [@r300]\]. RORα mRNA is expressed at low levels in DP thymocytes and at high levels in SP thymocytes, while it is decreased in mature CD8^+^ and increased in mature CD4^+^ T lymphocytes. B220^+^ B lymphocytes express low levels of RORα. The total number of thymocytes and splenocytes is greatly diminished in RORα^-/-^ mice and is associated with a loss of DP thymocytes and a corresponding increase in the percentage of DN and SP thymocytes \[[@r67]\]. In RORα^-/-^ spleen, both mature T and B lymphocytes were significantly reduced, suggesting that RORα plays a critical role in lymphocyte development.

No differences were observed between RORα^-/-^ and WT mice in the induction of CD4^+^ and CD8^+^ T lymphocyte proliferation in response to anti-CD3 or lipopolysaccharide (LPS), nor in the induction of cytokines by TNFα \[[@r67]\]. In contrast, the induction of IL-6 and tumor necrosis factor α was greatly increased in RORα^-/-^ mast cells and macrophages after LPS treatment \[[@r67]; [@r167]\]. These results indicate that at least in certain immune cells, RORα functions as a negative regulator of cytokine expression. Although the mechanism of this repression is not fully understood, RORα has been reported to positively regulate the expression of IKBα, a negative regulator of the NF-κB signaling pathway \[[@r53]\]. On this basis, it was concluded that RORα might function as a negative regulator of inflammation.

RORs and T cell lineage specification
=====================================

Role of RORs in Th17 cell differentiation
-----------------------------------------

Recent studies identified a critical role for RORs in the regulation of lineage specification in helper T cells \[[@r42]; [@r43]; [@r58]; [@r85]; [@r132]; [@r139]; [@r140]; [@r183]; [@r321]; [@r339]\]. Differentiation into different effector CD4^+^ T cell lineages, T helper (Th) 1, Th2, Th17, and T regulatory (T~reg~ or Th3) cells is initiated through an interaction of dendritic cells with uncommitted (naïve) CD4^+^ T helper cells (Thp). Th1, Th2, T~reg~, and Th17 are characterized by their synthesis of specific cytokines and their immuno-regulatory functions ([Figure 6](#fig6){ref-type="fig"}). Interferon γ is the signature cytokine produced by Th1 cells, while IL-4, IL-5 and IL-13 are major cytokines produced by Th2 cells. The recently discovered Th17 cells produce IL-17A (IL-17), IL-17F, IL-21, and IL-22 as major cytokines, while T~reg~ cells synthesize IL-10 and TGFβ1 \[[@r20]; [@r43]; [@r58]; [@r111]; [@r246]\]. T helper and T~reg~ cells play a critical role in several inflammatory responses, including adaptive immune responses to various pathogens. Host defense is coordinated by the proinflammatory Th1, Th2, and Th17 cells, while T~reg~ cells are involved in the down regulation and contraction of an immune inflammatory response. Th17 cells are believed to be the major proinflammatory cells involved in autoimmunity, while T~reg~ cells protect against autoimmunity \[[@r58]; [@r85]; [@r140]; [@r183]; [@r321]\]. Differentiation along different lineages is initiated by dendritic cells, which process and present (microbial) antigens to TCRs on Thp cells. Interaction of dendritic cells with different classes of pathogens results in the activation of different pathways and the release of different cytokines that subsequently interact with receptors on Thp cells and either guide or repress their differentiation along different lineages ([Figure 6](#fig6){ref-type="fig"}). The latter involves the activation of distinct signaling cascades and transcription factors and the synthesis of other cyto/chemokines and cyto/chemokine receptors that are part of additional positive and negative feedback loops. For example, induction of Th1 cells by IL-12 involves the transcription factors STAT4, STAT1, and T-bet, while differentiation along the Th2 lineage in response to IL-4 requires STAT6 and GATA3 \[[@r111]; [@r226]\]. Differentiation into T~reg~ cells and Th17 cells is often reciprocal, involving several positive and negative regulatory networks that favor one or the other lineage \[[@r19]; [@r20]; [@r58]; [@r85]; [@r111]; [@r139]; [@r140]; [@r183]; [@r246]; [@r309]; [@r321]\]. This includes a yin-yang relationship between RORγt and FOXP3 expression and their regulation by several cytokines, transforming growth factor β (TGFβ), and ATRA.

Littman, Cua, and their colleagues were first to report that RORγt is required for the differentiation of naïve CD4^+^ T cells into Th17 cells \[[@r139]; [@r140]; [@r201]\]. This was supported by findings from several other laboratories \[[@r58]; [@r184]; [@r338]; [@r339]\]. RORγt is induced during differentiation of antigen-stimulated Thp cells along the Th17 lineage in response to IL-6 or IL-21 and TGFβ ([Figure 7](#fig7){ref-type="fig"}). Cells deficient in IL-6 do neither express RORγt nor IL-17F and IL23R \[[@r168]; [@r184]; [@r338]\]. IL-6 mediates its action through activation of STAT3. Deficiency in STAT3 greatly impaired the activation of RORγt expression and Th17 differentiation, suggesting that this induction is STAT3-dependent \[[@r114]; [@r237]; [@r338]\]. Inversely, deficiency in suppressor of cytokine signaling 3 (SOCS3), a negative regulator of STAT3 activity, enhances Th17 differentiation \[[@r41]\]. Whether STAT3 regulates RORγt expression directly by binding to the RORγt promoter needs to be established. Additional evidence for a role of RORγt in Th17 differentiation came from studies showing that Thp cells isolated from RORγ null mice exhibited a marked reduction in their ability to undergo differentiation along the Th17 lineage \[[@r139]; [@r237]; [@r338]\]. Conversely, exogenous expression of RORγt in Thp cells greatly increased the expression of IL-17 cytokines and IL23R in the absence of cytokines. Subsequent studies showed that, like RORγt, RORα is highly induced during Th17 cell differentiation in a STAT3-dependent manner \[[@r339]\] ([Figure 7](#fig7){ref-type="fig"}). Deficiency in RORα reduced IL-17 and IL23R, but not IL-17F or IL-22 expression, while exogenous expression of RORα in Thp cells or Jurkat cells enhanced IL-17, IL-17F, IL-22, and IL23R expression \[[@r62]; [@r339]\]. These observations indicate that RORα also functions as a positive regulator of Th17 differentiation, suggesting a degree of functional redundancy between RORγt and RORα. This was consistent with findings showing that Th17 differentiation was completely impaired in Thp cells deficient in both RORα and RORγ \[[@r337]; [@r339]\]. Thus, both RORα and RORγt are required for optimal differentiation of Thp cells into Th17 cells; however, RORγt appears to be the major player in this process because RORγt deficiency has a more pronounced effect on the expression of Th17 cytokines than loss of RORα. Whether RORα and RORγ have any unique roles in the regulation of gene expression during or after Th17 differentiation needs further study.

In addition to the induction of RORγt, IL-17, and IL-17F, differentiation along the Th17 lineage is associated with increased expression of IL-21 and IL23R \[[@r1]; [@r168]; [@r183]; [@r237]; [@r323]; [@r348]\]. The induction of IL-21 in response to IL-6 involves direct binding of STAT3 to the IL-21 promoter. IL-21, through its activation of STAT3, synergizes with IL-6 and TGFβ to induce RORγt and IL-17 expression \[[@r237]; [@r244]; [@r348]\] ([Figure 7](#fig7){ref-type="fig"}). IL-21 expression is not affected in RORγ-deficient mice, suggesting that this regulation occurs upstream of RORγ. IL-21 is also expressed in T follicular helper T (Tfh) cells, another novel T cell subset that develops independent of RORs \[[@r238]\]. In contrast to IL-21, the induction of IL23R is greatly reduced in RORγ-deficient mice, suggesting that its expression is regulated by RORγt. IL23R itself is part of a positive feedback loop; it allows IL-23 to bind, thereby reinforcing Th17 differentiation through activation of STAT3 \[[@r140]; [@r209]; [@r338]; [@r348]\].

Suppression of ROR transcriptional activity by FOXP3
----------------------------------------------------

T~reg~ and Th17 cells are reciprocally regulated, involving several positive and negative regulatory networks \[[@r20]; [@r58]; [@r85]; [@r140]; [@r183]; [@r237]; [@r321]; [@r347]; [@r349]\]. The balance between the expression of RORγt and the forkhead box transcription factor p3 (FOXP3) plays a critical role in determining whether uncommitted CD4^+^ T helper cells differentiate into T~reg~ or Th17 cells ([Figure 6](#fig6){ref-type="fig"}). FOXP3 contains a repressor domain in the N-terminal half and a C2H2 zinc finger, a leucine zipper, and a forkhead domain at its C-terminal half, allowing the protein to function as an activator or repressor of gene transcription \[[@r32]; [@r35]; [@r187]; [@r195]\]. FOXP3 is predominantly expressed in CD4^+^CD25^+^ T~reg~ cells, where it plays an important role in directing differentiation \[[@r32]; [@r194]; [@r347]\]. In addition, it regulates several functional properties and contributes to the survival of T~reg~ cells. FOXP3-deficient mice lack T~reg~ cells and are highly susceptible to inflammatory disease \[[@r27]; [@r82]\]. Conversely, induction or exogenous expression of FOXP3 inhibits Th17 differentiation.

Regulation of FOXP3 expression by TGFβ and IL-6 plays a critical role in T~reg~ and Th17 lineage determination \[[@r20]; [@r42]; [@r58]; [@r140]; [@r321]\]. In the presence of TCR engagement, TGFβ induces FOXP3 expression and T~reg~ differentiation in murine Thp cells. Although TGFβ can moderately enhance the expression of RORα and RORγt, FOXP3 is induced at much higher levels, thereby shifting the ROR/FOXP3 balance towards FOXP3 and T~reg~ differentiation \[[@r19]; [@r40]; [@r78]; [@r168]; [@r237]; [@r309]; [@r318]; [@r333]; [@r349]\] ([Figure 7](#fig7){ref-type="fig"}). Addition of IL-6 or IL-21 inhibits the induction of FOXP3 by TGFβ and activates RORα and RORγt expression, thereby shifting the ROR/FOXP3 balance in favor of Th17 differentiation. These observations indicate that FOXP3 represses Th17 differentiation by antagonizing RORγt function rather than inhibiting its expression \[[@r62]; [@r134]; [@r140]; [@r337]; [@r349]\]. This antagonism is mediated through a direct interaction of FOXP3 with RORα and RORγt and involves the AF2 domain of RORs and an LXXLL motif within a region encoded by exon 2 of *FOXP3*. Mutation of this motif greatly inhibits the interaction of FOXP3 with RORs, but did not completely prevent FOXP3-mediated suppression of ROR activity. Transcriptional repression by FOXP3 involves an interaction with the histone acetyltransferase TIP60 and histone deacetylase HDAC7 through the 106-190 amino acid region of FOXP3 \[[@r187]\]. Deletion of this region diminishes the inhibitory effect of FOXP3 on ROR-mediated transactivation, while lack of both the LXXLL motif and the TIP60-HDAC7 interaction domain totally abolished the FOXP3-mediated repression \[[@r337]\]. Thus, the interaction of FOXP3, possibly in complex with TIP60 and HDAC, with RORs represses ROR transcriptional activity and consequently inhibits the activation of *IL-17* expression and Th17 differentiation by RORα and RORγt.

A number of other cytokines and transcription factors influence the balance between T~reg~ and Th17 differentiation. In contrast to IL-6, IL-21, and IL23, IL-2 inhibits RORγt expression and Th17 differentiation through a STAT5-dependent mechanism and promotes the generation of T~reg~ cells \[[@r140]; [@r184]\]. IL-10, in addition to inhibiting Th1 differentiation, also suppresses Th17 differentiation and the expression of RORγt and IL-17 \[[@r102]\]. Conversely, RORγt expression and Th17 differentiation is enhanced in IL-10^-/-^ spleen cells. Moreover, treatment of IL-10^-/-^ macrophages with LPS greatly induces RORγt and IL-17 expression. The increased expression of RORγ and IL-17 in IL-10^-/-^ spleen cells and LPS-treated macrophages was repressed by the addition of IL-10. In addition to the STAT transcription factors, interferon regulatory factor 4 (IRF4) has been reported to regulate T lineage commitment and to be required for Th17 differentiation \[[@r28]; [@r133]\]. IRF4 is essential for IL21-induced Th17 differentiation. The expression of RORα, RORγt, and IL-17 are significantly reduced in IRF4-deficient T cells, whereas the expression of FOXP3 is increased, indicating that IRF4 also plays a role in regulating the balance between Th17 and T~reg~ cells. Thus, the balance between Th17 and T~reg~ differentiation is under a complex control, involving multiple transcription factors.

Suppression of Th17 differentiation and RORγt expression by ATRA
----------------------------------------------------------------

Retinoids play an important role in the control of several immune functions, including the commitment of Thp cells to different lineages \[[@r141]; [@r142]\]. ATRA produced from retinol by dendritic cells has been demonstrated to negatively regulate Th1 and Th2 cell differentiation \[[@r141]\]. More recent studies showed that retinoic acid is a critical factor in controlling the balance between Th17 and T~reg~ cells \[[@r44]; [@r227]; [@r291]\]. Upon TCR activation, the differentiation of Thp cells into T~reg~ cells was shown to depend on both TGFβ and ATRA \[[@r16]; [@r44]; [@r74]; [@r291]\]. ATRA inhibited the induction of Th17 differentiation and down-regulated RORγt expression in response to TGFβ and IL-6, and instead promoted FOXP3 expression and the subsequent generation of T~reg~ cells ([Figure 7](#fig7){ref-type="fig"}). In addition to IL-17, ATRA also represses the expression of IL-23R and IL-6Rα. These findings are consistent with the concept that differentiation of TCR-activated Thp cells into Th17 or T~reg~ is decided by the balance between FOXP3 and RORγt.

The precise mechanism of the inhibition of RORγt and induction of FOXP3 expression by ATRA still needs to be elucidated. Because IL-2 induces FOXP3 expression through the activation of STAT5, ATRA could enhance FOXP3 through increased IL-2 expression and STAT5 activation. However, FOXP3 induction by ATRA was found to be independent of IL-2 and STAT5 \[[@r74]\]. Binding to and activation of retinoic acid receptors α, β, and γ (RARs), in a heterodimeric complex with RXRs, is the major mechanism by which ATRA regulates gene transcription \[[@r219]\]. The retinoid (4-\[E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl\] benzoic acid (TTNPB), a synthetic RAR pan-agonist, effectively induced FOXP3 expression and T~reg~ differentiation, while an RAR-antagonist inhibited this induction by ATRA. These observations suggested that these effects of ATRA are mediated by RARs. Study of RAR-selective retinoids showed that RARα rather than RARγ was found to be the key player in the induction of FOXP3 and suppression of Th17 differentiation \[[@r74]\]. This was supported by data demonstrating that ATRA was able to promote the conversion of RARβ- and RARγ-deficient Thp cells into FOXP3^+^ cells, but not in Thp cells isolated from RARα-deficient mice \[[@r124]\]. It has been suggested that stimulation of the TGFβ signaling pathway might partly explain the increased T~reg~ differentiation by ATRA in the presence of TGFβ. This is supported by findings showing that ATRA increases the expression and phosphorylation of SMAD3 \[[@r328]\]. However, recent studies indicated that the induction of T~reg~ cells by ATRA is mediated by an indirect mechanism involving alleviation of the inhibition of FOXP3 expression by CD4^+^CD44^hi^ memory cells \[[@r124]\].

The inhibition of Th17 differentiation by ATRA might explain the protective effects of retinoids in animal models of autoimmune disease \[[@r319]; [@r328]\]. Supplementation with ATRA suppresses the development of experimental autoimmune encephalomyelitis (EAE) in mice by inhibiting proinflammatory responses. This suppression appears to be related to the inhibition of Th17 cell generation rather than to an increase in T~reg~ cells.

Regulation of IL-17 by RORs
---------------------------

Although the expression of IL-17, IL-17F, IL-22, and IL23R during Th17 differentiation is dependent on RORs, there is little understanding of whether these genes are regulated directly by RORs. Several studies have identified the presence of functional ROREs in a 6 kb promoter flanking region of the *IL-17* gene \[[@r134]; [@r339]; [@r345]\]. However, there is no consensus on which ROREs are most important in driving *IL-17* expression by RORγt. Recent studies indicated that the CNS2 region at the *il17-il17f* locus (between -4 and -6 kb) undergoes chromatin remodeling in response to IL-6/TGFβ \[[@r3]\]. Subsequent studies showed that the regulation of *IL-17* by RORs involves this CNS2 regulatory region \[[@r339]\]. This putative enhancer sequence contains two ROREs that are able to bind ROR directly and mediate transcriptional activation by RORα and RORγt, while the 1kb proximal promoter region was nonresponsive to ROR. ChIP analysis showed that RORs are associated *in vivo* with a region containing the CNS2 site \[[@r339]\]. These observations indicate that the induction of IL-17 by RORs is mediated through this region and suggest that IL-17 is a direct target of ROR transcriptional regulation.

In addition to RORs, several other transcription factors, including STAT3, have been reported to positively regulate *IL17* transcription \[[@r339]; [@r348]\]. The induction by STAT3 is mediated through binding to the promoter region of the *IL17* gene. Expression of constitutively active STAT3 induces *IL17* when co-expressed with RORγt, but has little effect in RORγ-deficient T cells, indicating that the induction of *IL17* expression by STAT3 is dependent on the presence of RORγt.

Runt-related transcription factor 1 (RUNX1) is another transcription regulator that promotes Th17 differentiation by enhancing *RORγt* and *IL17* expression \[[@r345]\]. The activation of *IL17* expression by RUNX1 is mediated through two Runx-binding sites that are near the ROREs in the *IL17* promoter region. In addition, it was shown that RUNX1 interacts directly with RORγt and acts synergistically with RORγt to optimally activate *IL17* expression. Expression of FOXP3 inhibits this activation by interacting directly with RORγt and RUNX1, thereby repressing their transcriptional activity.

RORs and autoimmune disease
---------------------------

Th17 cells have been implicated in autoimmune disease and other inflammatory conditions in humans, including lupus, arthritis, multiple sclerosis, atopic dermatitis, psoriasis, asthma, and inflammatory bowel disease \[[@r21]; [@r132]; [@r140]\]. IL-17 induces the secretion of a variety of chemokines, cytokines, metalloproteinases, and other proinflammatory mediators and promotes the recruitment of neutrophils. Mice lacking IL-17 are resistant to collagen-induced arthritis (CIA) and EAE, a model for multiple sclerosis. Neutralizing IL-17 with antibodies suppresses CNS autoimmune inflammation \[[@r58]; [@r85]; [@r132]; [@r169]; [@r288]\]. Inversely, transfer of Th17 cells aggravates the disease. Rag1^-/-^ mice reconstituted with CD4^+^ splenocytes or bone marrow from RORγ- or RORα-deficient mice are less susceptible to EAE than mice reconstituted with WT CD4^+^ splenocytes or bone marrow \[[@r139]; [@r339]\]. Similar experiments with Rag1^-/-^ mice reconstituted with cells from mice deficient in both RORα and RORγ showed a complete resistance to EAE. Recent studies using the adoptive transfer model of colitis showed that transfer of RORγ-null T cells failed to increase mucosal IL-17 cytokine levels and did not induce colitis, while treatment with IL-17A restored colitis after transfer of RORγ-null T cells \[[@r186]\]. These studies indicate that loss of RORα/γt function greatly reduces the susceptibility to the development of autoimmune disease in mice. These observations suggest that by controlling Th17 differentiation and IL-17 expression, RORγt and RORα play a critical role in the regulation of inflammatory responses ([Figure 2](#fig2){ref-type="fig"}). Therefore, RORs might function as potential drug targets for therapeutic intervention into autoimmune disease, including chronic colitis and multiple sclerosis.

RORs and lung inflammation
--------------------------

RORα^sg/sg^ and RORγ^-/-^ mice are less susceptible to ovalbumin (OVA)-induced lung inflammation, which serves as an experimental model for allergic airway disease \[[@r145]; [@r297]\]. The infiltration of inflammatory cells, including eosinophils, neutrophils, and lymphocytes into peribronchiolar and perivascular regions in lungs and in bronchial alveolar lavage fluid, was significantly less in OVA-challenged RORα^sg/sg^ mice compared to WT mice, and the induction of Th2 cytokines IL-4, IL-5, and IL-13 was greatly compromised. Analysis of gene expression profiles demonstrated that the expression of many genes implicated in inflammatory responses, including the chemokines *TARC*, eotaxin-2 (*Ccl24*), MIP-1a (*Ccl3*), MCP-2 (*Ccl8*), and RANTES (*Ccl5*), acute response proteins, mucins *MUC5b* and *MUC5ac*, are induced to a significantly smaller degree in lungs from OVA-challenged RORα^sg/sg^ mice than those from WT mice. Together, these observations show that RORα^sg/sg^ mice develop a less severe allergic inflammatory response. Interestingly, RORα^sg/sg^ mice are more susceptible to LPS-induced inflammation \[[@r282]\]. The mechanism of this increased sensitivity is not quite yet understood.

The allergic response in RORγ^-/-^ mice is also severely impaired, as evidenced by attenuated eosinophilic pulmonary inflammation and reduction in CD4^+^ lymphocytes and level of Th2 cytokines/chemokines \[[@r297]\]. OVA sensitized and challenged RORγ^-/-^ animals showed unexpected increases in TNF-α, IL-2, IL-10, and IFN-γ and reciprocal reductions in IL-4, IL-5, and IL-13. This shift in cytokine profiles, coupled with reduced IgG1 and elevated IgG2c levels in the sera of OVA-exposed RORγ^-/-^ mice, reveals a critical role for RORγ in the regulation of immunoglobulin production and balance between different T helper cell populations. The decreased inflammatory response in RORγ^-/-^ mice might be in part related to the role RORγ plays in Th17 lineage determination \[[@r139]; [@r140]; [@r339]\]. Interestingly, mice lacking IL-17 have been reported to exhibit an attenuated eosinophilic lung inflammation and Th2 cytokine production, while IL-10, which is produced by T~reg~ cells, has been reported to inhibit allergic inflammation \[[@r307]; [@r308]\]. Moreover, mice deficient in the *IL17* gene, but not *IL17F*, also exhibited reduced Th2 responses in a similar asthma model \[[@r336]\]. Thus, the reduction in Th17 cells in RORγ^-/-^ mice and the observed increase in IFN-γ (Th1) and IL-10 (T~reg~) in OVA-challenged RORγ^-/-^ mice is consistent with the hypothesis that the decreased susceptibility to allergic lung inflammation in these mice might be related to shifts in the commitment to different Th lineages. This hypothesis is consistent with the concept that crosstalk between lineage-specific transcription factors plays an important role in lineage specification.

RORs and circadian rhythm
=========================

Circadian behavior of ROR expression
------------------------------------

Circadian rhythms are daily cycles of behavioral and physiological changes that are regulated by endogenous circadian clocks \[[@r115]; [@r138]; [@r164]; [@r191]; [@r270]; [@r271]\]. The circadian clock impacts virtually all physiological functions and behavior. It is therefore not surprising that abnormalities in circadian rhythm are implicated in an increasing number of diseases, including sleep and mood disorders, diabetes, obesity, and cancer \[[@r13]; [@r90]; [@r136]; [@r191]; [@r207]; [@r302]\].

A number of studies have established links between nuclear receptor function and expression, the circadian regulatory circuitry, and the regulation of various physiological processes \[[@r2]; [@r64]; [@r104]; [@r128]; [@r147]; [@r192]; [@r253]; [@r304]; [@r334]; [@r335]\]. Many nuclear receptors, including RORs, display, at least in some tissues, rhythmic patterns of expression during the circadian cycle, indicating that their expression is controlled by the circadian clock. RORα expression shows a weak circadian oscillation in liver, kidney, retina, and lung \[[@r2]; [@r155]; [@r298]; [@r304]; [@r334]\]. In the SCN, RORα exhibits a rhythmic pattern of expression with a peak at CT6-8. A similar circadian profile was observed for RORβ, while RORγ is not expressed in the SCN \[[@r269]; [@r290]; [@r304]\]. RORβ2 displays a rhythmic expression pattern in mouse pineal gland and retina, with a maximum at CT18 \[[@r6]; [@r304]\]. RORγ exhibits an oscillatory expression pattern in liver, brown adipose tissue, and kidney, but not in skeletal muscle and thymus \[[@r104]; [@r147]; [@r157]; [@r304]; [@r305]; [@r334]\]. In these tissues, RORγ is expressed at low levels during the day and at optimum levels at night.

Mice deficient in RORα or RORβ exhibit an aberrant circadian behavior \[[@r2]; [@r204]; [@r268]; [@r269]\], while no abnormalities in circadian behavior have been noticed in RORγ^-/-^ mice \[[@r192]\]. RORα^sg/sg^ mice display an anomalous, slightly decreased, free-running period of locomotor activity and an altered feeding pattern during the circadian cycle \[[@r2]; [@r103]; [@r268]\], while RORβ^-/-^ mice display an extended period of free-running rhythmicity under conditions of constant darkness \[[@r6]; [@r204]\].

Regulation of clock genes by ROREs
----------------------------------

Nearly every mammalian cell type contains its own circadian oscillator. The oscillators in peripheral tissues operate in a self-sustained, cell-autonomous manner \[[@r138]; [@r164]; [@r191]; [@r258]; [@r259]; [@r262]; [@r271]\]. Their synchronization is coordinated by signals originating from the master circadian clock residing in the SCN of the anterior hypothalamus. The phase of the master oscillator is set by the light-dark cycle input received by both visual and non-visual photoreceptor systems in the retina.

At the molecular level, the clockwork consists of an integral network of several interlocking negative feedback and positive feedforward loops. The basic molecular circuitry of circadian clocks is analogous between tissues. A major positive loop consists of the basic helix-loop-helix/PAS-type transcriptional activators BMAL1 and CLOCK or its paralog NPAS2, while two cryptochrome (CRY) and three period proteins (PER) are involved in the negative control of the oscillator \[[@r5]; [@r51]; [@r52]; [@r138]; [@r259]; [@r270]; [@r271]\] ([Figure 8](#fig8){ref-type="fig"}). BMAL1-CLOCK heterodimers positively regulate the circadian expression of many genes, including PER and CRY, through interaction with E-box enhancers (CACGTG) in the promoter regulatory region of target genes. When PER and CRY proteins accumulate to a critical level, they in turn repress BMAL1:CLOCK-mediated transcription, including their own transcription, by interacting directly with BMAL1-CLOCK complexes. This subsequently leads to reduced levels of PER and CRY protein and to a new cycle of activation and repression.

The core loop is further regulated by several accessory pathways, including one in which the D box-binding proteins, the activator D site-binding protein (DBP) and the repressor E4 promoter binding-protein 4 (E4BP4 or NFIL3), play a role, and another that involves regulation by RORs and REV-ERBs through ROREs \[[@r30]; [@r164]; [@r192]; [@r253]; [@r254]; [@r305]\]. ROREs have been identified in several clock genes, including BMAL1, CLOCK, and CRY1 \[[@r104]; [@r171]; [@r234]; [@r254]; [@r268]; [@r304]\]. The BMAL1 gene, which contains two ROREs in its promoter region, is positively regulated by RORs, whereas REV-ERBs repress BMAL1 transcription ([Figure 8](#fig8){ref-type="fig"}). Mutation of these ROREs abolishes the circadian rhythmicity of the BMAL1 promoter activation, indicating that these response elements are essential for rhythmic transcriptional regulation of BMAL1. Further study showed that BMAL1 expression is elevated and its rhythmicity impaired in fibroblasts deficient in both REV-ERBα and β, but fibroblasts deficient in only one of the REV-ERB receptors still retain BMAL1 rhythmicity \[[@r192]\]. These observations suggested that REV-ERBα and β are functionally redundant and essential for the rhythmic expression of BMAL1. However, REV-ERBα and β are not required for the rhythmicity of several other clock genes, including PER and CRY.

In contrast to REV-ERBs, RORs are not required for the rhythmicity of BMAL1 expression \[[@r192]\]. RORα^sg/sg^ fibroblasts, which lack RORα and do not express either RORβ or γ, display rhythmic oscillations of BMAL1 or PER2 promoter-regulated luciferase reporter expression that are similar to that observed in WT fibroblasts. These findings are in agreement with studies showing that the rhythmic expression of various clock proteins, including PER2, CRY1, BMAL1, and CLOCK, was not altered in RORα^sg/sg^ or RORγ null mice \[[@r192]; [@r268]\]. However, the peak expression levels of BMAL1, as well as that of several other RORE-containing clock genes, including CLOCK, CRY1, and NPAS2, were reduced in both RORα^sg/sg^ and RORγ null mice, while those of PER2 and DBP were not changed. Regulation of BMAL1 by RORs is supported by findings showing that RORs interact with ROREs in the BMAL1 promoter and induce transcriptional activation through this promoter region \[[@r2]; [@r104]; [@r268]; [@r305]\]. This activation of BMAL1 expression by RORs appears to be mediated through the coactivator PGC-1α \[[@r193]\]. Thus, RORs are not essential for the rhythmic expression of BMAL1 or other clock genes, but do regulate their level of expression. Moreover, in contrast to common regulators of the circadian clock, which appear to be ubiquitously expressed, RORs exhibit a much more restricted pattern of expression, consistent with the view that they are not common constituents of clock regulatory circuitry mechanisms. In addition to modulating the expression of several components of the circadian clock, the major function of RORs might be regulating the rhythmic expression of downstream target genes. Therefore, RORs may function as intermediates that couple the circadian oscillators with the cyclic control of various physiological processes, including energy homeostasis, lipid, and xenobiotic metabolism \[[@r157]; [@r192]; [@r268]\] ([Figure 8](#fig8){ref-type="fig"}).

Regulation of circadian expression of RORs
------------------------------------------

As mentioned above, in several tissues RORs display a rhythmic expression during the circadian cycle \[[@r192]; [@r245]; [@r268]; [@r304]; [@r305]; [@r306]\]. Several functional elements relevant to circadian rhythm have been identified in the promoter of RORs. Functional D-boxes were identified in *RORα* and *RORβ*, suggesting regulation by members of the bZIP-family. The proximal promoter of *RORγ1* and *RORα1* contain one functional E-box, while that of *RORα4* contains two E-boxes, suggesting regulation by BMAL1/CLOCK. Based on the presence of functional ROREs in the promoter regions of RORs, it was proposed that their expression might be controlled by REV-ERBs proteins. The observation that in liver and several other tissues the expression of RORγ1 and REV-ERBs is inversely related, is consistent with the view that REV-ERBs function as repressors of RORγ1 transcription and regulate the rhythmicity of RORγ1 expression ('repressor-antiphasic-to-activator' mechanism) \[[@r192]; [@r305]; [@r306]\]. RORγ1 appears to have a minor role in controlling the transcription of REV-ERBs because their expression is only moderately affected in liver from RORγ null mice. Analysis of RORγ1 mRNA expression in liver of BMAL1^-/-^ mice showed that the rhythmicity of RORγ1 expression was almost totally abolished and that RORγ1 expression at all CTs was greatly elevated \[[@r99]; [@r192]\]. It was concluded that, at least in liver, the loss of REV-ERB repressor expression observed in BMAL1^-/-^ mice is likely responsible for the lack of rhythmicity and relieved or elevated RORγ1 expression in these mice \[[@r192]\]. Expression was particularly increased at CT6-8, a time at which REV-ERB is normally highly expressed. How then is RORγ1 transcription activated in liver of BMAL1^-/-^ mice? It was suggested that the expression of RORs might be driven by non-circadian, tonic signals, such as the cAMP:cAMP response element-binding (CREB) pathway \[[@r191]; [@r192]; [@r239]\].

SIRT1 and RORγ expression
-------------------------

Posttranslational modifications, including phosphorylation by casein kinases and other kinases and acetylation, play a critical role in regulating protein-protein interactions, the nuclear localization, transcriptional activity, and turnover of clock proteins \[[@r73]; [@r87]; [@r164]; [@r262]\]. CLOCK, which functions as a histone acetyltransferase, has been implicated in chromatin remodeling during circadian rhythm \[[@r57]\]. In addition to histones, CLOCK also acetylates other proteins, including BMAL1 \[[@r125]\]. Recently, sirtuin 1 (SIRT1), a NAD^+^-dependent deacetylase, was identified as an important regulator of circadian gene expression. It was suggested that it provides a functional link between metabolic activity and circadian control \[[@r9]; [@r15]; [@r233]\]. SIRT1 deacetylates histones and a number of transcriptional regulators, and was shown to bind BMAL1-CLOCK-PER2 complexes in a circadian-dependent manner. SIRT1 catalyzes deacetylation of PER2, thereby facilitating its degradation by the proteasome system. Consequently, absence of SIRT1 expression leads to high levels of PER2, resulting in diminished BMAL1-CLOCK transcriptional activity and repression of clock-controlled target genes, including reduced expression of PER2 and CRY1 ([Figure 8](#fig8){ref-type="fig"}). In addition, SIRT1 induces deacetylation of BMAL1 at Lys^537^, which reduces the efficacy of CRY to interact with and silence CLOCK-BMAL1 \[[@r233]\]. Although RORγ1 is expressed at low levels in mouse embryo fibroblasts (MEFs), its expression is greatly diminished in SIRT1 KO MEFs. Because RORγ1 expression is positively regulated by BMAL1-CLOCK, its repression in SIRT1 KO MEFs may be related to the silencing of BMAL1-CLOCK activity. Inversely, the down-regulation of RORγ1 in SIRT1 KO MEFs may, at least in part, account for the reduced expression of BMAL1 observed in these cells.

It has been become increasingly clear that SIRT1 functions as a link between the circadian rhythm circuitry, cellular metabolism, and nuclear receptors, including RORs \[[@r9]; [@r233]; [@r273]\]. One such link involves PGC-1α. SIRT1 has been reported to induce deacetylation and activation of PGC-1α, which functions as a coactivator of several nuclear receptors \[[@r263]\]. This, together with the circadian regulation of nuclear receptor expression, is part of the complex mechanism by which nuclear receptors regulate cellular metabolism. It is interesting to note that SIRT1 activity peaks around the same time as RORγ1 mRNA expression (at CT16). Further studies are needed to elucidate the precise molecular and physiological connections between SIRT1 and ROR activity.

RORs and cellular metabolism
============================

Changes in lipid metabolism and ROR-deficient mice
--------------------------------------------------

Accumulating evidence indicates that RORs play an important role in the regulation of several metabolic pathways, particularly lipid and steroid metabolism \[[@r24]; [@r64]; [@r89]; [@r146]; [@r147]; [@r157]; [@r181]; [@r182]; [@r188]; [@r200]; [@r256]; [@r257]; [@r312]; [@r313]; [@r314]\]. RORα^sg/sg^ mice on a normal diet display a pronounced hypo-α-lipoproteinemia and have lower levels of total plasma cholesterol, high density lipoprotein (HDL), ApoA1, the major constituent of HDL, ApoC3, ApoA2, and triglycerides compared to WT mice. The reduced expression of the reverse cholesterol transporters ABCA1 and ABCA8/G1 in the liver and of ApoA1 in the intestine may in part be responsible for the reduced HDL levels. Functional ROREs have been identified in the promoter regulatory region of APOC2 and APOA1 \[[@r257]; [@r312]\]. The RORE within the APOAI promoter was shown to interact selectively with RORα1, but not with RORα2 or α3. Although human ApoA5 was identified as a RORα target gene, its expression was not altered in liver of RORα^sg/sg^ mice \[[@r89]; [@r188]\]. Upon aging, RORα^sg/sg^ mice are less susceptible to the development of hepatic steatosis than WT mice \[[@r181]\]. In addition, despite their higher food consumption, aging RORα^sg/sg^ mice exhibit a reduced body fat index. Fat cells in brown and white adipose tissue are smaller and the level of triglycerides is lower in liver of RORα^sg/sg^ mice than WT mice. The increased food intake correlates with an observed reduction in leptin expression. As observed for aging RORα^sg/sg^ mice, 2-3 months-old RORα^sg/sg^ mice are less susceptible to high fat diet-induced obesity and steatosis \[[@r181]\].

In contrast to RORα^sg/sg^ mice, cholesterol and triglyceride levels were unaltered in RORγ^-/-^ mice; however, these mice have a somewhat reduced blood glucose level \[[@r157]\]. Mice deficient in both RORα and RORγ (DKO) exhibit similar changes in cholesterol, triglycerides, and glucose as observed for single KO mice. Comparison of gene expression profiles from livers of WT, RORα-deficient, RORγ-deficient, and DKO mice revealed that RORα and RORγ can function as positive and negative regulators of gene expression. In addition to regulating the expression of a distinct set of genes, suggesting unique regulatory functions, some genes are only up- or down-regulated in DKO mice, suggesting a degree of functional redundancy between RORα and RORγ \[[@r157]\]. The latter is likely related to their similarities in RORE binding affinities. However, the main functions of RORα and RORγ appear to be distinct from each other.

RORs in the regulation of (lipid) metabolism
--------------------------------------------

The effect of RORα on triglyceride homeostasis can be due to the changes in the regulation of a number of genes, including those involved in the control of lipogenesis and fatty acid oxidation. The expression of sterol regulatory element-binding protein 1, isoform c (SREBP1c), which is a critical regulator of lipogenesis and several lipogenic genes, was significantly reduced in liver and skeletal muscle of RORα^sg/sg^ mice \[[@r181]; [@r313]\]. This was associated with a suppression of several SREBP1c target genes, including fatty acid synthase (FAS). LXRs and carbohydrate response element-binding protein (ChREBP) have been reported to be critical factors in the regulation of SREBP1c \[[@r36]; [@r247]; [@r315]\]. However, the expression of LXRs and ChREBP was not significantly altered in liver from RORα^sg/sg^ mice. ChIP and promoter analysis indicated that SREBP1c transcription is under the selective and direct control of RORα4, the predominant isoform of RORα in liver \[[@r181]\]. It was concluded that RORα positively regulates lipogenesis through increased SREBP1c expression. The latter might, at least in part, explain the reduced adiposity in RORα^sg/sg^ mice.

The expression of estrogen-related receptor α (ERRα) and peroxisome proliferators-activated receptors (PPARs) α, β, and γ, which are implicated in the control of lipid homeostasis as well, was not changed in RORα^sg/sg^ mice \[[@r55]; [@r299]\]. However, the expression of the coactivators PGC-1α and β, which are involved in the regulation of oxidative metabolism and gluconeogenesis, was increased in liver and brown adipose tissue, respectively \[[@r192]\]. Expression of lipin 1, which has multiple functions in lipid metabolism and glucose homeostasis in several tissues, was found to be enhanced in liver and adipose tissues of RORα^sg/sg^ mice \[[@r181]\]. Loss of lipin 1 function leads to hepatic steatosis and hypertriglyceridemia, but reduced adipose tissue \[[@r248]\]. Lipin 1 has been reported to interact directly with the nuclear receptor PPARα and coactivator PGC-1α in a complex that modulates fatty acid oxidation gene expression in hepatocytes \[[@r80]\]. Thus, increased levels of PGC-1 and lipin 1 in RORα^sg/sg^ liver might enhance oxidative metabolism and account for the increased expression of acyl-coenzyme A dehydrogenase ACADM. However, expression of carnitine palmitoyltransferases 1A and 1B (CPT1A/B), which are also involved in fatty acid oxidation, was not significantly affected in liver of RORα^sg/sg^ mice. Clearly, further studies are needed to understand the complex relationships between RORα, its regulation of lipid metabolism, and its effects on obesity and triglyceride levels.

Regulation of CYP7b1 and sulfotransferases
------------------------------------------

Several of the genes regulated by RORs encode proteins involved in Phase I and II enzymes that are important in the metabolism of xenobiotics, drugs, environmental chemicals, and various endogeneous compounds, including steroids and bile acids \[[@r157]; [@r313]\]. These enzymes play an important role in elimination and detoxification of endogenous and exogenous compounds. One of the genes regulated by RORs is oxysterol 7alpha-hydroxylase (Cyp7b1), which plays a role in the alternative pathway of cholesterol metabolism, whereas the expression of Cyp7a1 and Cyp27, which play a role in the major cholesterol metabolic pathway, was not affected in ROR-deficient mice. Cyp7b1, which is preferentially expressed in liver of male mice, was down-regulated in RORα^sg/sg^ mice and was affected only to a small degree in RORγ^-/-^ mice \[[@r157]; [@r313]\]. RORα regulates Cyp7b1 expression directly by binding to an RORE at nt -951 in the promoter regulatory region of the Cyp7b1 gene. This RORE preferentially binds RORα rather than RORγ. These observations suggest that RORα functions as a positive modulator of Cyp7b1 expression. Recent studies identified CYP2C8, which play an important role in drug metabolism, as a putative ROR target gene in human hepatocytes \[[@r39]\]. Both RORα and RORγ were able to enhance the activation through a RORE within the CYP2C8 promoter and to enhance CYP2C8 expression in human primary hepatocytes.

Sulfotransferase 1e1 (Sult1e1) is among the genes most dramatically induced in liver of RORα^sg/sg^ mice, while the expression is not significantly changed in RORγ^-/-^ mice, suggesting that it is under the selective control of the RORα signaling pathway \[[@r157]\]. Sult1e1 expression in liver is restricted to female mice. It catalyzes the sulfonation of estrogen and estrone, thereby increasing their solubility and facilitating their transport and excretion \[[@r63]\]. Sult2a1 expression is induced in liver of both RORα^sg/sg^ and RORγ^-/-^ mice, suggesting that both RORα and RORγ function as negative modulators of Sult2a1 expression. It catalyzes the sulfonation of procarcinogens, xenobiotics, hydroxysteroids, and bile acids, including dehydroepiandrosterone and lithocholic acid \[[@r162]\]. In addition to these sulfotransferases, the expression of several members of the hydroxysteroid dehydrogenase family, many of which are involved in the biosynthesis or inactivation of steroid hormones, are regulated by RORs \[[@r157]\]. These observations suggest that RORs, and particularly RORα, play an important role in the regulation of specific steps in bile acid and steroid metabolism. The control of several sulfotransferases by RORα is interesting with regard to reports showing that cholesterol sulfate functions as a ligand of RORα \[[@r153]; [@r154]\]. Possibly other sulfated steroid or cholesterol metabolites might function as high affinity RORα ligands and be part of regulatory feedback loops that control specific steps in steroid/cholesterol metabolism.

Several metabolic genes regulated by RORs have been reported to be target genes of other nuclear receptors \[[@r4]; [@r152]; [@r163]; [@r255]; [@r264]\]. For example, Sult2a1 expression is regulated by several receptors, including constitutive androstane receptor (CAR), hepatocyte nuclear factor 4α (HNF4α), and pregnane X receptor (PXR) \[[@r77]; [@r199]\]. An overlap between genes regulated by RORα and liver X receptors (LXRs) was particularly evident \[[@r98]; [@r314]\]. CD36, Sult1e1, and Sult2a1 are induced while Cyp7b1 expression is inhibited by activated LXR, a pattern that is the inverse of that observed for RORα \[[@r157]; [@r313]; [@r314]\]. This raised the possibility of potential crosstalk between the RORα and LXR pathways. However, this crosstalk does not occur at the level of the regulation of LXR or ROR expression because LXRα and β expression were not altered in liver of RORα^sg/sg^ mice, while RORα expression was unchanged in liver of LXR DKO mice \[[@r181]; [@r313]\]. Although in cultured cells, competition between LXR and RORα for binding common coactivators has been observed, it is not clear whether such a competition is physiologically significant. *In vivo*, the inverse regulation of common targets by RORα and LXR may involve several mechanisms, including crosstalk between ROR and LXR transcriptional complexes bound to their respective response elements within the promoter of the same target gene.

RORs and muscle
---------------

RORα and RORγ mRNA are highly expressed in skeletal muscle, suggesting a regulatory role for these receptors in myogenesis or muscle function \[[@r14]; [@r126]; [@r180]\]. This is supported by observations showing that RORα^sg/sg^ mice develop muscular atrophy; however, the mechanism underlying this phenotype has not been clearly identified. C2C12 skeletal muscle cells have been used to examine the function of RORα and RORγ in myogenesis and lipid homeostasis. Expression of a dominant-negative RORα, lacking the LBD, delays the morphological differentiation of myotubes and induction of muscle-specific genes, such as the helix-loop-helix transcription factors MyoD and myogenin, transcription factors that are critical for myotubule differentiation \[[@r180]\]. In addition, the expression of fatty acid translocase (FAT/CD36) and fatty acid binding protein 3 (FABP3), which are involved in lipid and fatty acid uptake, and of lipoprotein lipase (LPL), CPT-1, and acyl-CoA-synthetase-4 (ACS4) involved in triglyceride hydrolysis and hydroxylation, respectively, were reduced in these cells \[[@r182]\]. Expression of RORγ in C2C12 cells was shown to increase the expression of several genes, including CD36, FABP4, LPL, UCP3, fructose transporter GLUT5, adiponectin receptor 2 (ADPR2), and IL-15, suggesting a role for RORγ in the regulation of lipid metabolism in muscle \[[@r256]\].

RORs and cancer
===============

RORs and increased cancer susceptibility
----------------------------------------

A number of studies have provided evidence suggesting a role for RORs in cancer. Mice deficient in the expression of RORγ exhibit a high incidence of thymic lymphomas that metastasize frequently to liver and spleen \[[@r149]; [@r303]\]. As a consequence, the lifespan of RORγ null mice is greatly reduced. The enhanced lymphoma formation may be related to changes in thymic homeostasis observed in RORγ KO mice \[[@r174]; [@r292]\]. Although the molecular mechanism underlying enhanced lymphoma formation has not yet been established, it may be related to the dysregulation of differentiation and proliferation in RORγ^-/-^ thymocytes. Interestingly, type B leukemogenic virus (TBLV), which causes T-cell lymphomas in mice, was found to be frequently integrated at the RORγ locus \[[@r26]\]. However, in contrast to RORγ null mice, RORγ expression correlated positively with lymphomas. Whether RORγ is implicated in human lymphomas requires further study.

Another potential link between RORγ and cancer is emerging from studies showing increased expression of Th17-associated genes, including RORγ, IL-17, and IL-23, in gastric tumors, an increase in the population of circulating Th17 cells in gastric cancer patients \[[@r344]\], and a high incidence of Th17 cells at sites of ovarian cancer \[[@r220]\]. These elevated levels of proinflammatory cytokines may contribute to cancer pathogenesis. Alterations in RORγt expression or activity may cause changes in the Th17 cell population and production of proinflammatory cytokines, thereby affecting cancer progression positively or negatively.

Although no explicit links between RORα and cancer have been established, a number of studies have indicated a possible a role for RORα in cancer development. The *RORα* gene spans a 730 kb genomic region that is located in the middle of the common fragile site FRA15A within chromosomal band 15q22.2 \[[@r279]; [@r350]\]. Common fragile sites are highly unstable genomic regions found in all individuals and are hotspots for deletions and other genetic alterations that may lead to altered expression and function of genes encoded within these regions. Common fragile sites have been implicated in several human diseases and are associated with a number of different cancer types \[[@r279]\]. Genomic instability within FRA15A might lead to changes in the expression of RORα and play a role in the development of certain cancers. This hypothesis is consistent with observations showing that RORα mRNA expression is often down-regulated in tumor cell lines and primary cancer samples \[[@r350]\]. Moreover, studies examining gene expression profiles in various cancers identified *RORα* as a gene commonly down-regulated in several tumor types, particularly breast and lung cancer \[[@r196]\]. Analysis of the methylation status of a series of genes identified *RORα* as one of methylation-silenced genes in gastric cancer cell lines \[[@r332]\]. The latter is in agreement with the concept that reduced expression of RORα expression positively correlates with tumor formation.

RORs, hypoxia and stress
------------------------

Several studies have revealed a connection between RORα expression and hypoxia. Hypoxia is important in normal physiology and in several pathologies, including ischemia, stroke, heart attack, chronic kidney disease, and cancer progression \[[@r252]; [@r274]\]. Oxygen sensing is a key control mechanism of vasculogenesis and tumor growth. Hypoxia triggers a multifaceted cellular response in which the transcription factor hypoxia-inducible factor HIF-1α plays a central role. Several studies have reported that RORα4, but not RORα1, expression is highly induced under hypoxic conditions in a variety of cell types \[[@r17]; [@r37]; [@r38]; [@r218]\]. Conditions that mimic effects of hypoxia, including exposure to cobalt chloride and the iron chelator, desferrioxamine, also enhance RORα4 expression \[[@r38]\]. In addition to hypoxia, several other stress conditions induce RORα4 expression, including H~2~O~2~ and several inducers of endoplasmic reticulum (ER) stress, including farnesol, thapsigargin, tunicamycin, and brefeldin \[[@r151]; [@r350]\]. These observations indicate a regulatory role for RORα4 in hypoxia and stress responses. Studies *in vivo* demonstrated that ischemia-induced angiogenesis was enhanced in RORα-deficient mice \[[@r18]\]. These observations suggest that RORα functions as an important negative modulator of angiogenesis. Angiogenesis is controlled by pro- and anti-angiogenic factors. Inflammatory cells and cytokines have also been implicated in the regulation of angiogenesis. Thus, changes in the expression of pro- and/or anti-angiogenic or inflammatory genes in RORα^sg/sg^ mice might account for the observed increased angiogenesis. The expression of the pro-angiogenic vascular endothelial growth factor (VEGF) was not changed in ischemia-induced angiogenesis in RORα^sg/sg^ mice; however, the level of interleukin 12 (IL-12), an anti-angiogenic cytokine, was found to be reduced. Clearly, additional studies are needed to understand the role of RORα in angiogenesis.

The induction of RORα4 expression by hypoxia is mediated by HIF-1α through an interaction with a hypoxia response element (HRE) in the proximal promoter region of RORα4 \[[@r37]\]. Subsequent studies showed that activation of RORα4 by hypoxia was dependent on an interaction between HIF-1α and the transcription factors Sp1/Sp3 bound to GC-rich sequences adjacent to the HRE \[[@r218]\]. Recently, exogenous expression of RORα was reported to increase the level of HIF1α and VEGF protein, while knockdown of RORα expression by siRNAs reduced HIF1α and VEGF expression \[[@r160]\]. Moreover, RORα was found to enhance capillary tube formation by human umbilical vein endothelial cells. These observations suggest that RORα may function as an amplifier of HIF1α-mediated responses by hypoxia. RORα was reported to stimulate hypoxia response element (HRE)-dependent transcriptional activation of a reporter. The enhancement in HIF1α-mediated transactivation by RORα was found to be related to increased stability of HIF-1α protein and to involve a direct interaction between HIF-1α and the DBD of RORα \[[@r160]\]. Several of the experiments in this study were based on activation of RORα by melatonin, a rather controversial putative ligand of RORα. Thus, additional studies are needed to understand the role of RORα and melatonin in hypoxia.

RORα1 and RORγ1 have also been implicated in other stress-related regulatory functions. RORα1 has been reported to provide protection to oxidative stress-induced apoptosis in cortical neurons by increasing the expression of antioxidant proteins glutathione peroxidase 1 (GPX1) and peroxiredoxin 6 (Prx6), thereby reducing the accumulation of stress-related reactive oxygen species (ROS) \[[@r25]\]. Ectopic expression of RORγ in C2C12 cells has been reported to enhance UCP3 expression and decrease ROS production \[[@r256]\]. Identification of genes regulated by RORα might shed light on its precise role in hypoxia- and stress-induced responses.

Summary
=======

Recent studies of RORs have greatly widened our understanding of the physiological roles of this nuclear receptor subfamily and provided exciting clues about their critical functions in embryonic development, cellular differentiation and proliferation, immunity, cellular metabolism, and circadian rhythm. The rhythmic pattern of expression of RORs in certain tissues and the regulation of several components of the circadian clock and metabolic pathways by RORs are consistent with the emerging view that the controls of these processes are coupled. RORs function as a subcomponent of the circadian oscillator and integrate the control of the circadian clocks and the rhythmic pattern of expression of (metabolic) genes and, as such, regulate the cyclic nature of several physiological processes, including energy homeostasis, lipid and xenobiotic metabolism. The reduced susceptibility of RORα-deficient mice to hepatic steatosis and obesity suggests a role for RORα in energy homeostasis. The critical regulatory roles that RORs have in thymopoiesis, development of several secondary lymphoid tissues, and Th17 lineage specification are highly relevant to a variety of immune responses and inflammatory disorders, including autoimmune diseases and asthma. The greatly decreased susceptibility to allergic airway inflammation, experimental autoimmune encephalomyelitis, and colitis in ROR-deficient mice raises the possibility that RORs might serve as potential novel targets for chemotherapeutic strategies to intervene in these disease processes. The discovery that ROR activity can be modulated by ligands strongly supports this prospect. Hopefully, the next decade will see the discovery of ROR-specific, clinically-useful (ant)agonists.
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AF2

:   activation function 2

ApoA

:   apolipoprotein

ATRA

:   all-*trans* retinoic acid

ATXN1

:   ataxin 1

BMAL1

:   brain and muscle ARNT-like 1

CaMKIV

:   calmodulin-dependent kinase IV

ChIP

:   Chromatin immunoprecipitation

CRX

:   cone-rod homeobox factor

CRY

:   cryptochrome

CT

:   circadian time

Cyp7b1

:   oxysterol 7alpha-hydroxylase

DBD

:   DNA-binding domain

DBP

:   D site-binding protein

DHR3

:   Drosophila hormone receptor 3

DKO

:   double knockout

DP

:   double positive

EAE

:   experimental autoimmune encephalomyelitis

EGR

:   early growth response gene

FOXP3

:   forkhead box transcription factor p3

HDAC

:   histone deacetylase

HDL

:   high density lipoprotein

HIF1α

:   hypoxia-inducible factor α

IL

:   interleukin

IRF4

:   interferon regulatory factor 4

ISP

:   immature single positive

LBD

:   ligand binding domain

LPS

:   lipopolysaccharide

LTi

:   lymphoid tissue inducer cells

LXR

:   liver X receptor

NCOA

:   nuclear receptor coactivator

NCOR

:   nuclear receptor corepressor

NK

:   natural killer

Obfc2a

:   oligonucleotide/oligosaccharide-binding fold-containing 2a

Opn

:   opsin

OVA

:   ovalbumin

PER

:   period protein

PGC-1

:   peroxisome proliferator-activated receptors coactivator

PND

:   postnatal day

PPAR

:   peroxisome proliferators-activated receptor

PPs

:   Peyer's patches

RAR

:   retinoic acid receptor

RIP140

:   receptor-interacting protein 140

ROR

:   RAR- or retinoid-related orphan receptor

RORE

:   ROR response element

RUNX1

:   runt-related transcription factor 1

RXR

:   retinoid X receptor

sg

:   staggerer

SCA1

:   spinocerebellar ataxia type 1

SCN

:   suprachiasmatic nucleus

Shh

:   Sonic hedgehog

SIRT1

:   sirtuin 1

SP

:   single positive

SRC

:   steroid receptor coactivator

SREBP1c

:   sterol regulatory element-binding protein 1, isoform c

STAT

:   signal transducer and activator of transcription

SULT

:   sulfotranferase

TGFβ

:   transforming growth factor β

Th

:   T helper

Thp

:   uncommitted (naïve) CD4^+^ T helper cells

TIP60

:   Tat-interactive protein, 60 kD

T~reg~

:   T regulatory

UBE2I

:   ubiquitin-conjugating enzyme I

WT

:   wild type
